Compositions for increasing the half-life of therapeutic agents in livestock animals and methods of use thereof

JP2023552456A5Inactive Publication Date: 2024-12-09INVETX INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023534323
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-07
Filing Date
2021-12-01
Publication Date
2024-12-09
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a lack of guidance in existing technologies for increasing the half-life of polypeptide therapeutics, such as antibodies, in domestic animals, which is crucial for effective therapeutic applications.

Method used

Development of Fc region variants with specific amino acid substitutions that enhance binding to FcRn in domestic animals, particularly at acidic pH, leading to increased half-life and serum persistence of polypeptides.

Benefits of technology

The Fc region variants exhibit enhanced binding to FcRn, resulting in prolonged half-life and improved therapeutic efficacy of polypeptides in domestic animals.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Compositions and methods of use for increasing the half-life of one or more polypeptides in livestock animals are provided. The compositions comprise a variant IgG Fc region.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Patent Application No. 63 / 122,365, filed on 7 December 2020, the contents of which are incorporated herein by reference in their entirety.

[0002] This disclosure generally relates to polypeptides in livestock animals whose half-life is increased compared to their wild-type equivalents (e.g., fusion polypeptides such as polypeptide-Fc domain fusions; or binding molecules such as ligand-binding portions of antibody or receptor-Fc fusions).

[0003] Sequence List The entire contents of the following sequence listing electronically submitted via the USPTO EFS-WEB server are incorporated herein by reference for all purposes, as authorized and provided for in MPEP §1730 II.B.2(a). The sequence listing is contained in the electronically submitted text file identified below:

[0004] File name: 47406-0017WO1_Sequence_Listing.txt

[0005] Date created: December 1, 2021

[0006] Size (bytes): 64,960 bytes [Background technology]

[0007] The Fc region of antibodies plays many, though not limited to, functional roles, including protecting antibodies from degradation via the lysosomal pathway and mediating antibody effector functions. As the use of antibodies as therapeutic agents in livestock increases, emphasis is being placed not only on selecting the optimal Fab, but also on combining it with an appropriate Fc to obtain the desired half-life and effector function.

[0008] In the art, there are few guidelines regarding increasing the half-life of polypeptide therapeutics (e.g., antibodies) used in livestock. This disclosure addresses this lack by providing Fc region variants that improve the serum persistence of polypeptides (e.g., antibodies) in livestock. [Overview of the project]

[0009] Provided herein are Fc regions (e.g., Fc region variants of IgG) or FcRn-binding fragments of livestock animals useful for therapeutic polypeptides. This disclosure features polypeptides that exhibit increased binding to FcRn in livestock animals compared to a control polypeptide (e.g., the Fc region of IgG, which is the wild-type equivalent). In some cases, these polypeptides exhibit increased binding to FcRn in livestock animals at pH 5.5, pH 6.0, and / or pH 6.5 compared to the control polypeptide. In some cases, these polypeptides can bind to FcRn in livestock animals at acidic pH (e.g., pH 5.5, pH 6.0, or pH 6.5) than at neutral pH (e.g., pH 7.0, 7.1, 7.2, 7.3, 7.4, or 7.5). In some cases, these polypeptides bind to FcRn in livestock animals at higher levels at pH 5.5 and / or pH 6.0 than at pH 7.4. This disclosure relates in part to polypeptides with an increased half-life in livestock animals compared to their wild-type equivalent. For example, binding molecules (e.g., ligand-binding portions of antibodies or receptors) with increased half-lives compared to versions of binding molecules not bound to the Fc region or its FcRn binding region disclosed herein are provided. Enzyme-Fc region fusions, ligand-Fc region fusions, nanobody-Fc fusions, and peptide-Fc region fusions are also provided, the fusions having increased half-lives compared to their wild-type equivalents. In addition to having one or more substitutions that increase half-life (compared to the wild-type Fc region of the same species of livestock animal), the Fc region may also include other substitutions resulting in, for example, increased effector function, decreased effector function, increased binding to protein A, and / or decreased polypeptide heterogeneity (e.g., by removing one or more post-translational modifications in the Fc region). The Fc region sequences of livestock animals may be derived from any antibody of the livestock animal. In some cases, the Fc region sequences of livestock animals are derived from IgG, its subclasses of which are described separately herein.

[0010] This disclosure comprises a recombinant protein comprising (1) a binding domain or fragment thereof that specifically binds to an epitope of a ligand or protein, wherein the binding domain is (2) bound to a domain comprising an Fc region (CH2+CH3 region) or an FcRn binding region of a livestock animal disclosed herein. In some cases, the binding domain comprises (i) six complementarity-determining regions (CDRs), e.g., of a livestock animal or a human / humanized antibody; (ii) a nanobody; (iii) a soluble receptor-binding domain or a ligand-binding fragment thereof that binds to a ligand; and (iv) an extracellular domain of a livestock animal receptor protein.

[0011] This disclosure also provides compositions comprising (1) a first polypeptide comprising a first Fc region (e.g., a CH2 domain, a CH3 domain, or a CH2+CH3 domain) comprising an Fc region variant of livestock animal IgG described herein, and (2) a second polypeptide comprising a second Fc region comprising an Fc region variant of livestock animal IgG described herein. The first and second polypeptides can associate via the first and second Fc regions. In some cases, the amino acid sequences of the first and second Fc regions are the same. In other cases, the amino acid sequences of the first and second Fc regions are different (e.g., amino acids 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25).

[0012] In some embodiments, the Fc region variant is an Fc variant of porcine IgG selected from the group consisting of IgG1a, IgG1b, IgG2a, IgG2b, IgG3, IgG4a, IgG4b, IgG5a, IgG5b, IgG6a, and IgG6b.

[0013] In some embodiments, the Fc region variant is an Fc variant of bovine IgG selected from the group consisting of IgG1, IgG2, and IgG3.

[0014] In some embodiments, the Fc region variant is an Fc variant of equine IgG selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgG5, IgG6, and IgG7.

[0015] In some embodiments, the Fc region variant is an Fc variant of sheep IgG selected from the group consisting of IgG1, IgG2, and IgG3.

[0016] In some embodiments, the Fc region variant is an Fc variant of goat IgG selected from the group consisting of IgG1, IgG2, and IgG3.

[0017] Also disclosed are fusion molecules comprising the Fc region variants and polypeptides of the domestic animal IgG disclosed herein. In some cases, the Fc region variant of the domestic animal IgG is covalently bound to the polypeptide (e.g., via a hinge region or linker). In some cases, the polypeptide is a ligand-binding domain of a domestic animal receptor protein, an extracellular domain of a domestic animal receptor protein, or an antigen-binding domain. In some cases, the polypeptide is selected from the ligand-binding domain or extracellular domain of IL-13Rα1 or IL-13Rα2, domestic animal erythropoietin (EPO), domestic animal CTLA4, domestic animal LFA3, domestic animal VEGFR1 / VEGFR3, domestic animal IL-1R, domestic animal GLP-1 receptor agonist, and domestic animal thrombopoietin-binding peptide. In some cases, the polypeptide is a scFv, nanobody, or single-domain antibody. In some cases, the Fc region variant of IgG is a variant of the Fc region of a domestic animal IgG1a antibody. In some cases, the Fc region variant of IgG is a variant of the Fc region of a domestic animal IgG1b antibody. In some cases, the Fc region variant of IgG is a variant of the Fc region of a domestic animal IgG2 antibody.

[0018] In some aspects, the present disclosure provides a polypeptide comprising the Fc region variant of IgG from a domestic animal or its FcRn binding region, wherein the polypeptide has an amino acid substitution at at least one position selected from the group consisting of: (i) a position corresponding to amino acid position 250 of wild-type IgG from a domestic animal, wherein the amino acid substitution is selected from the group consisting of S250Q, S250E, T250Q, T250E, I250Q, I250E, A250Q, A250E, V250Q, and V250E; (ii) a position corresponding to amino acid position 252 of wild-type IgG from a domestic animal, wherein the amino acid substitution is selected from the group consisting of M252Y, M252W, M252F, T252Y, T252W, T252F, K252Y, K252W, and K252F; (iii) a position corresponding to amino acid position 254 of wild-type IgG from a domestic animal, wherein the amino acid substitution is selected from the group consisting of S254T, S254R, S254K, S254H, T254R, T254K, and T254H; (iv) a position corresponding to amino acid position 256 of wild-type IgG from a domestic animal, wherein the amino acid substitution is selected from the group consisting of T256A, T256D, T256E, M256A, M256D, M256E, K256A, K256D, and K256E; (v) a position corresponding to amino acid position 286 of wild-type IgG from a domestic animal, wherein the amino acid substitution is selected from the group consisting of S286Y, S286F, S286W, S286L, S286D, S286E, T286Y, T286F, T286W, T286L, T286D, and T286E; (vi) a position corresponding to amino acid position 309 of wild-type IgG from a domestic animal, wherein the amino acid substitution is selected from the group consisting of Q309V, Q309D, and Q309E; (vii) A position corresponding to amino acid position 311 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, Q311H, E311V, E311K, E311R, E311L, E311H, K311V, K311R, K311L, K311H, D311V, D311K, D311R, D311L, and D311H; (viii) A position corresponding to amino acid position 426 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of A426Y, A426F, A426H, V426Y, V426F, V426H, G426Y, G426F, and G426H; (ix) A position corresponding to amino acid position 428 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of M428L, M428Y, M428F, H428L, H428Y, and H428F; (x) A position corresponding to amino acid position 434 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W, N434Y, H434A, H434F, H434S, H434W, and H434Y; and (x) The position corresponding to amino acid position 436 of wild-type IgG of livestock animals, the amino acid substitution is selected from the group consisting of Y436H, T436H, F436H, and V436H, Here, based on EU numbering, the amino acid positions provide a polypeptide that exhibits increased binding affinity to the FcRn of livestock animals compared to the Fc domain of wild-type IgG.

[0019] In some embodiments, the livestock animal is a pig.

[0020] In some embodiments, the polypeptide includes an amino acid substitution at at least one position selected from the group consisting of: (i) A position corresponding to amino acid position 250 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of T250Q, T250E, I250Q, and I250E; (ii) A position corresponding to amino acid position 252 of wild-type IgG in domestic animals, wherein the amino acid substitution is selected from the group consisting of M252Y, M252W, and M252F; (iii) A position corresponding to amino acid position 254 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of S254T, S254R, S254K, and S254H; (iv) A position corresponding to amino acid position 256 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of T256A, T256D, and T256E; (v) A position corresponding to amino acid position 286 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of T286Y, T286F, T286W, T286L, T286D, and T286E; (vi) A position corresponding to amino acid position 309 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of Q309V, Q309D, and Q309E; (vii) A position corresponding to amino acid position 311 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, Q311H, E311V, E311K, E311R, E311L, and E311H; (viii) A position corresponding to amino acid position 426 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of A426Y, A426F, A426H, V426Y, V426F, and V426H; (ix) A position corresponding to amino acid position 428 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of M428L, M428Y, M428F, H428L, H428Y, and H428F; (x) A position corresponding to amino acid position 434 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W, N434Y, H434A, H434F, H434S, H434W, and H434Y; and (xi) A position corresponding to amino acid position 436 of wild-type IgG of a domestic animal, wherein the amino acid substitution is selected from the group consisting of Y436H and T436H.

[0021] In some embodiments, the polypeptide includes an amino acid substitution at at least one position selected from the group consisting of: (i) The position corresponding to amino acid position 252 of wild-type IgG in domestic animals, where the amino acid substitution is M252Y; (ii) The position corresponding to amino acid position 286 of wild-type IgG in domestic animals, wherein the amino acid substitution is T286E; (iii) A position corresponding to amino acid position 309 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q309D or Q309V; (iv) A position corresponding to amino acid position 311 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q311V; (v) The position corresponding to amino acid position 426 of wild-type IgG in domestic animals, wherein the amino acid substitution is A426Y; (vi) The position corresponding to amino acid position 428 of wild-type IgG in domestic animals, wherein the amino acid substitution is M428Y; and (vii) A position corresponding to amino acid position 434 of wild-type IgG of a domestic animal, wherein the amino acid substitution is selected from the group consisting of N434Y.

[0022] In some embodiments, the Fc of wild-type IgG is the Fc of porcine IgG, which contains an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11.

[0023] In some embodiments, the domesticated animal is a cattle.

[0024] In some embodiments, the polypeptide includes an amino acid substitution at at least one position selected from the group consisting of: (i) A position corresponding to amino acid position 250 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of T250Q and T250E; (ii) A position corresponding to amino acid position 252 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of M252Y, M252W, M252F, T252Y, T252W, and T252F; (iii) A position corresponding to amino acid position 254 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of S254T, S254R, S254K, S254H, T254R, T254K, and T254H; (iv) A position corresponding to amino acid position 256 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of T256A, T256D, and T256E; (v) A position corresponding to amino acid position 286 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of T286Y, T286F, T286W, T286L, T286D, and T286E; (vi) A position corresponding to amino acid position 309 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of Q309V, Q309D, and Q309E; (vii) A position corresponding to amino acid position 311 of wild-type IgG in domestic animals, wherein the amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, and Q311H; (viii) A position corresponding to amino acid position 426 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of A426Y, A426F, A426H, V426Y, V426F, and V426H; (ix) A position corresponding to amino acid position 434 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W, and N434Y; and (x) A position corresponding to amino acid position 436 of wild-type IgG in domestic animals, wherein the amino acid substitution is Y436H.

[0025] In some embodiments, the polypeptide includes an amino acid substitution at at least one position selected from the group consisting of: (i) The position corresponding to amino acid position 252 of wild-type IgG in domestic animals, where the amino acid substitution is T252Y; (ii) The position corresponding to amino acid position 309 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q309V; (iii) A position corresponding to amino acid position 311 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q311V; (iv) A position corresponding to amino acid position 434 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of N434Y; (v) A position corresponding to amino acid position 436 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of Y436H.

[0026] In some embodiments, the Fc of wild-type IgG is the Fc of bovine IgG, which contains an amino acid sequence selected from the group consisting of SEQ ID NOs: 12-14.

[0027] In some embodiments, the domesticated animal is a horse.

[0028] In some embodiments, the polypeptide includes an amino acid substitution at at least one position selected from the group consisting of: (i) A position corresponding to amino acid position 250 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of T250Q, T250E, A250Q, A250E, V250Q, and V250E; (ii) A position corresponding to amino acid position 252 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of M252Y, M252W, M252F, K252Y, K252W, and K252F; (iii) A position corresponding to amino acid position 254 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of S254T, S254R, S254K, S254H, T254R, T254K, and T254H; (iv) A position corresponding to amino acid position 256 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of T256A, T256D, T256E, M256A, M256D, M256E, K256A, K256D, and K256E; (v) A position corresponding to amino acid position 286 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of S286Y, S286F, S286W, S286L, S286D, S286E, T286Y, T286F, T286W, T286L, T286D, and T286E; (vi) A position corresponding to amino acid position 309 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of Q309V, Q309D, and Q309E; (vii) A position corresponding to amino acid position 311 of wild-type IgG in domestic animals, wherein the amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, Q311H, K311V, K311R, K311L, and K311H; (viii) A position corresponding to amino acid position 426 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of A426Y, A426F, A426H, V426Y, V426F, V426H, G426Y, G426F, and G426H; (ix) A position corresponding to amino acid position 428 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of M428L, M428Y, and M428F; (x) A position corresponding to amino acid position 434 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W, N434Y, H434A, H434F, H434S, H434W, and H434Y; and (xi) A position corresponding to amino acid position 436 of wild-type IgG of a domestic animal, wherein the amino acid substitution is selected from the group consisting of Y436H, F436H, and V436H.

[0029] In some embodiments, the polypeptide includes an amino acid substitution at at least one position selected from the group consisting of: (i) The position corresponding to amino acid position 252 of wild-type IgG in domestic animals, where the amino acid substitution is M252Y; (ii) The position corresponding to amino acid position 286 of wild-type IgG in domestic animals, wherein the amino acid substitution is T286E; (iii) A position corresponding to amino acid position 309 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q309V; (iv) A position corresponding to amino acid position 311 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q311V; (v) The position corresponding to amino acid position 426 of wild-type IgG in domestic animals, where the amino acid substitution is G426Y; (vi) A position corresponding to amino acid position 434 of wild-type IgG of a domestic animal, wherein the amino acid substitution is selected from the group consisting of N434Y.

[0030] In some embodiments, the Fc of wild-type IgG is the Fc of horse IgG, which contains an amino acid sequence selected from the group consisting of SEQ ID NOs: 15-21.

[0031] In some embodiments, the domesticated animal is a sheep.

[0032] In some embodiments, the polypeptide includes an amino acid substitution at at least one position selected from the group consisting of: (i) A position corresponding to amino acid position 250 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of S250Q, S250E, T250Q, and T250E; (ii) A position corresponding to amino acid position 252 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of M252Y, M252W, M252F, T252Y, T252W, and T252F; (iii) A position corresponding to amino acid position 254 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of S254R, S254K, S254H, T254R, T254K, and T254H; (iv) A position corresponding to amino acid position 256 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of T256A, T256D, and T256E; (v) A position corresponding to amino acid position 286 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of T286Y, T286F, T286W, T286L, T286D, and T286E; (vi) A position corresponding to amino acid position 309 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of Q309V, Q309D, and Q309E; (vii) A position corresponding to amino acid position 311 of wild-type IgG in domestic animals, wherein the amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, Q311H, D311V, D311K, D311R, D311L, and D311H; (viii) A position corresponding to amino acid position 426 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of V426Y, V426F, and V426H; (ix) A position corresponding to amino acid position 428 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of M428L, M428Y, and M428F; (x) A position corresponding to amino acid position 434 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W, and N434Y; and (xi) A position corresponding to amino acid position 436 of wild-type IgG in domestic animals, wherein the amino acid substitution is Y436H.

[0033] In some embodiments, the Fc of wild-type IgG is the Fc of sheep IgG, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs. 22-24. In some embodiments, the polypeptide includes an amino acid substitution at at least one position selected from the group consisting of: (i) The position corresponding to amino acid position 252 of wild-type IgG in domestic animals, where the amino acid substitution is T252Y; (ii) The position corresponding to amino acid position 309 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q309V; (iii) A position corresponding to amino acid position 311 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q311V; (iv) A position corresponding to amino acid position 428 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of M428Y; (v) A position corresponding to amino acid position 434 of wild-type IgG of a domestic animal, wherein the amino acid substitution is selected from the group consisting of N434Y.

[0034] In some embodiments, the Fc of wild-type IgG is the Fc of sheep IgG, which contains an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-24.

[0035] In some embodiments, the domesticated animal is a goat.

[0036] In some embodiments, the polypeptide includes an amino acid substitution at at least one position selected from the group consisting of: (i) A position corresponding to amino acid position 250 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of S250Q, S250E, T250Q, and T250E; (ii) A position corresponding to amino acid position 252 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of M252Y, M252W, M252F, T252Y, T252W, and T252F; (iii) A position corresponding to amino acid position 254 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of S254R, S254K, S254H, T254R, T254K, and T254H; (iv) A position corresponding to amino acid position 256 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of T256A, T256D, T256E, K256A, K256D, and K256E; (v) A position corresponding to amino acid position 286 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of T286Y, T286F, T286W, T286L, T286D, and T286E; (vi) A position corresponding to amino acid position 309 of wild-type IgG in livestock animals, wherein the amino acid substitution is selected from the group consisting of Q309V, Q309D, and Q309E; (vii) A position corresponding to amino acid position 311 of wild-type IgG in domestic animals, wherein the amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, Q311H, K311V, K311R, K311L, K311H, D311V, D311K, D311R, D311L, and D311H; (viii) A position corresponding to amino acid position 426 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of A426Y, A426F, A426H, V426Y, V426F, and V426H; (ix) A position corresponding to amino acid position 428 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of M428L, M428Y, and M428F; (x) A position corresponding to amino acid position 434 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W, and N434Y; and (xi) A position corresponding to amino acid position 436 of wild-type IgG in domestic animals, wherein the amino acid substitution is Y436H.

[0037] In some embodiments, the Fc of wild-type IgG is the Fc of goat IgG, which contains an amino acid sequence selected from the group consisting of SEQ ID NOs. 25-27.

[0038] In some embodiments, the polypeptide comprises two or more of at least one amino acid substitutions, where the two or more amino acid substitutions are in different positions, and the polypeptide exhibits increased binding affinity to the FcRn of livestock animals compared to (a) the Fc domain of wild-type IgG of livestock animals and (b) a polypeptide comprising only one of the two or more amino acid substitutions.

[0039] In some embodiments, the polypeptide further comprises a binding domain. In some embodiments, the binding domain comprises (i) six complementarity-determining regions (CDRs) of an immunoglobulin molecule; (ii) a ligand-binding domain of a receptor protein in livestock animals; (iii) a nanobody; or (iv) an extracellular domain of a receptor protein in livestock animals.

[0040] In some embodiments, the binding domain specifically binds to antigens selected from the group consisting of NGF, TrKA, ADAMTS, IL-1, IL-2, IL-4, IL-4R, angiotensin type 1 (AT1) receptor, angiotensin type 2 (AT2) receptor, IL-5, IL-12, IL-13, IL-31, IL-33, CD3, CD20, CD47, CD52, and the complement system complex.

[0041] In some embodiments, the specific binding between the binding domain (e.g., the binding domain of an antibody) and the antigen is represented by a K D value. The K D is the ratio of the antibody dissociation rate (k off ) and the antibody association rate (k on ). The K D value can be determined by measuring the k on rate and the k off rate of a particular antibody / antigen interaction and then using the ratio of these values to calculate the K D value. The smaller the K D value, the greater the affinity of the antibody (or its binding domain) for its target. In some embodiments, the K D value of the specific binding is in the range of about 10 -6 to about 10 -12 (e.g., 10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 , 10 -11 , or 10 -12 ]>).

[0042] In some embodiments, the polypeptide further comprises a protein selected from the group consisting of EPO, CTLA4, LFA3, VEGFR1 / VEGFR3, IL-1R, IL-4R, GLP-1 receptor agonist, and thrombopoietin binding peptide.

[0043] In some embodiments, the polypeptide binds to FcRn of a domestic animal at a higher level at an acidic pH than at a neutral pH.

[0044] In some embodiments, the polypeptide binds to FcRn of a domestic animal at a higher level at pH 5.5 than at pH 7.4.

[0045] In some embodiments, the polypeptide binds to FcRn of a domestic animal at a higher level at pH 6.0 than at pH 7.4. ​

[0046] Pharmaceutical compositions comprising (i) the polypeptides described herein and (ii) pharmaceutically acceptable excipients are also disclosed herein.

[0047] This disclosure also extends to one or more nucleic acids that encode polypeptides described herein.

[0048] In another embodiment disclosed herein, one or more expression vectors comprising one or more nucleic acids described herein are provided. The disclosure also extends to a host cell comprising one or more nucleic acids disclosed herein or one or more expression vectors disclosed herein.

[0049] Furthermore, a method for preparing a polypeptide is also disclosed herein, the method including: (a) To provide one or more nucleic acids disclosed herein; (b) Expressing one or more nucleic acids in a host cell culture to produce polypeptides; and (c) Recover the polypeptide produced in (b) from the host cell culture.

[0050] In some embodiments, the method further includes formulating a polypeptide as a pharmaceutical formulation.

[0051] The disclosure also extends to a method for treating a disease or disorder in a livestock animal in need thereof, which comprises administering to the livestock animal an effective amount of a composition comprising the pharmaceutical composition disclosed herein.

[0052] The disclosure also extends to a method for preventing disease or disorder in livestock animals in need thereof, which comprises administering to the livestock animals an effective amount of a composition comprising the pharmaceutical composition disclosed herein.

[0053] In some embodiments, the disease or disorder is an allergy, chronic pain, acute pain, inflammatory disease, autoimmune disease, endocrine disorder, gastrointestinal disorder, cardiovascular disease, kidney disease, reproductive dysfunction, infection, or cancer.

[0054] In some embodiments, the disease or disorder is atopic dermatitis, allergic dermatitis, osteoarthritis pain, arthritis, anemia, or obesity.

[0055] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art in which the present invention pertains. Methods and materials similar to or equivalent to those described herein may be used to implement or verify the present invention, but exemplary methods and materials are described below. All publications, patent applications, patents, and other references referenced herein are incorporated by reference in their entirety. In case of any conflict, including definitions, this application shall prevail. Materials, methods, and examples are illustrative and not intended to limit the scope of the invention.

[0056] Other features and advantages of the present invention will become apparent from the following embodiments and claims for carrying out the invention. [Brief explanation of the drawing]

[0057] [Figure 1] This shows the amino acid sequence alignment of the wild-type Fc region of porcine IgG1a, sheep IgG1, bovine IgG1, horse IgG1, feline IgG1a, canine IgGB, and human IgG1. These sequences are assigned sequence numbers 30-36, respectively. [Figure 2A] The purity of porcine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 2B]The purity of porcine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 2C] The purity of porcine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 2D] The purity of porcine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 2E] The purity of porcine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 2F] The purity of porcine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 2G] The purity of porcine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 2H] The purity of porcine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 2I] The purity of porcine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 2J] The purity of porcine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 3A]The purity of sheep antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 3B] The purity of sheep antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 3C] The purity of sheep antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 3D] The purity of sheep antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 3E] The purity of sheep antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 3F] The purity of sheep antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 3G] The purity of sheep antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 3H] The purity of sheep antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 3I] The purity of sheep antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 3J]The purity of sheep antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 4A] The purity of bovine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 4B] The purity of bovine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 4C] The purity of bovine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 4D] The purity of bovine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 4E] The purity of bovine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 4F] The purity of bovine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 4G] The purity of bovine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 4H] The purity of bovine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 4I]The purity of bovine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 4J] The purity of bovine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, is shown. The purity of each antibody was >90%. [Figure 5A] The purity of equine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie Blue, is shown. The purity of each antibody was >90%. [Figure 5B] The purity of equine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie Blue, is shown. The purity of each antibody was >90%. [Figure 5C] The purity of equine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie Blue, is shown. The purity of each antibody was >90%. [Figure 5D] The purity of equine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie Blue, is shown. The purity of each antibody was >90%. [Figure 5E] The purity of equine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie Blue, is shown. The purity of each antibody was >90%. [Figure 5F] The purity of equine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie Blue, is shown. The purity of each antibody was >90%. [Figure 5G] The purity of equine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie Blue, is shown. The purity of each antibody was >90%. [Figure 5H]The purity of equine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie Blue, is shown. The purity of each antibody was >90%. [Figure 5I] The purity of equine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie Blue, is shown. The purity of each antibody was >90%. [Figure 5J] The purity of equine antibodies containing the Fc variant, determined by scanning densitometry of SDS / PAGE gels stained with Coomassie Blue, is shown. The purity of each antibody was >90%. [Figure 6A] This shows sensorgrams of kinetic-coupled data for porcine IgG variants and wild-type IgG. [Figure 6B] This shows sensorgrams of kinetic-coupled data for porcine IgG variants and wild-type IgG. [Figure 6C] This shows sensorgrams of kinetic-coupled data for porcine IgG variants and wild-type IgG. [Figure 6D] This shows sensorgrams of kinetic-coupled data for porcine IgG variants and wild-type IgG. [Figure 6E] This shows sensorgrams of kinetic-coupled data for porcine IgG variants and wild-type IgG. [Figure 6F] This shows sensorgrams of kinetic-coupled data for porcine IgG variants and wild-type IgG. [Figure 6G] This shows sensorgrams of kinetic-coupled data for porcine IgG variants and wild-type IgG. [Figure 6H] This shows sensorgrams of kinetic-coupled data for porcine IgG variants and wild-type IgG. [Figure 6I] This shows sensorgrams of kinetic-coupled data for porcine IgG variants and wild-type IgG. [Figure 6J] This shows sensorgrams of kinetic-coupled data for porcine IgG variants and wild-type IgG. [Figure 7A]This shows sensorgrams of kinetic-coupled data for sheep IgG variants and wild-type IgG. [Figure 7B] This shows sensorgrams of kinetic-coupled data for sheep IgG variants and wild-type IgG. [Figure 7C] This shows sensorgrams of kinetic-coupled data for sheep IgG variants and wild-type IgG. [Figure 7D] This shows sensorgrams of kinetic-coupled data for sheep IgG variants and wild-type IgG. [Figure 7E] This shows sensorgrams of kinetic-coupled data for sheep IgG variants and wild-type IgG. [Figure 7F] This shows sensorgrams of kinetic-coupled data for sheep IgG variants and wild-type IgG. [Figure 7G] This shows sensorgrams of kinetic-coupled data for sheep IgG variants and wild-type IgG. [Figure 7H] This shows sensorgrams of kinetic-coupled data for sheep IgG variants and wild-type IgG. [Figure 7I] This shows sensorgrams of kinetic-coupled data for sheep IgG variants and wild-type IgG. [Figure 7J] This shows sensorgrams of kinetic-coupled data for sheep IgG variants and wild-type IgG. [Figure 8A] This shows sensorgrams of kinetics-bound data for bovine IgG variants and wild-type IgG. [Figure 8B] This shows sensorgrams of kinetics-bound data for bovine IgG variants and wild-type IgG. [Figure 8C] This shows sensorgrams of kinetics-bound data for bovine IgG variants and wild-type IgG. [Figure 8D] This shows sensorgrams of kinetics-bound data for bovine IgG variants and wild-type IgG. [Figure 8E] This shows sensorgrams of kinetics-bound data for bovine IgG variants and wild-type IgG. [Figure 8F]This shows sensorgrams of kinetics-bound data for bovine IgG variants and wild-type IgG. [Figure 8G] This shows sensorgrams of kinetics-bound data for bovine IgG variants and wild-type IgG. [Figure 8H] This shows sensorgrams of kinetics-bound data for bovine IgG variants and wild-type IgG. [Figure 8I] This shows sensorgrams of kinetics-bound data for bovine IgG variants and wild-type IgG. [Figure 8J] This shows sensorgrams of kinetics-bound data for bovine IgG variants and wild-type IgG. [Figure 9A] This shows sensorgrams of kinetics-coupled data for horse IgG variants and wild-type IgG. [Figure 9B] This shows sensorgrams of kinetics-coupled data for horse IgG variants and wild-type IgG. [Figure 9C] This shows sensorgrams of kinetics-coupled data for horse IgG variants and wild-type IgG. [Figure 9D] This shows sensorgrams of kinetics-coupled data for horse IgG variants and wild-type IgG. [Figure 9E] This shows sensorgrams of kinetics-coupled data for horse IgG variants and wild-type IgG. [Figure 9F] This shows sensorgrams of kinetics-coupled data for horse IgG variants and wild-type IgG. [Figure 9G] This shows sensorgrams of kinetics-coupled data for horse IgG variants and wild-type IgG. [Figure 9H] This shows sensorgrams of kinetics-coupled data for horse IgG variants and wild-type IgG. [Figure 9I] This shows sensorgrams of kinetics-coupled data for horse IgG variants and wild-type IgG. [Figure 9J] This shows sensorgrams of kinetics-coupled data for horse IgG variants and wild-type IgG. [Modes for carrying out the invention]

[0058] The use of polypeptides (e.g., antibodies, ligand-binding domains of receptors, enzymes, ligands, peptides) is increasing as therapeutic agents for the prevention and treatment of a wide variety of diseases affecting livestock animals. In particular, for the prevention or treatment of chronic diseases that require repeated polypeptide administration, it is important to develop polypeptides with long half-lives.

[0059] Accordingly, this disclosure features immunoglobulin Fc regions or FcRn-binding regions of livestock animals that contain mutations that improve the half-life of one or more polypeptides containing these sequences in livestock animals. Polypeptides containing these domains and methods of using them are also disclosed. These peptides can be used for a variety of therapeutic and diagnostic applications.

[0060] Where values ​​are given as a range, it should be understood that the description includes disclosure of all possible subranges within that range and specific numerical values ​​that fall within that range, regardless of whether a specific numerical value or subrange is explicitly stated. All numerical notations, such as pH, temperature, time, concentration, and molecular weight, including ranges, are approximations and may vary as appropriate in increments of 1.0 or 0.1 (+) or (-), or by + / - 15%, 10%, 5%, or 2%. It should be understood that all numerical notations are preceded by the word "approximately," although this is not always explicitly stated. It should also be understood that the reagents described herein are merely illustrative, and their equivalents are known in the art, although this is not always explicitly stated.

[0061] When the term "approximately" is used herein to refer to a measurable value such as a quantity or concentration, it means that the specified quantity may vary by 20%, 10%, 5%, 1%, 0.5%, or 0.1%.

[0062] Pork antibodies Pigs typically possess 11 IgG heavy chains, known as IgG1a, IgG1b, IgG2a, IgG2b, IgG3, IgG4a, IgG4b, IgG5a, IgG5b, IgG6a, and IgG6b. These heavy chains represent 11 distinct subclasses of porcine IgG. The amino acid and DNA sequences of these heavy chains are available from the GENBANK database. Illustrative examples of the amino acid sequences of the CH2 and CH3 domains of the Fc region of each of the 11 porcine IgG heavy chains are shown below (the CH2 domain is underlined), along with the GenBank accession number (amino acid sequence or the mRNA sequence from which the amino acid sequence originates) for each heavy chain Fc region:

[0063] Fc sequence of porcine (Sus scrofa) IgG IgG1a (GenBank AAA52219.1) [ka]

[0064] IgG1b (GenBank AAA52216.1) [ka]

[0065] IgG2a (GenBank U03779) [ka]

[0066] IgG2b (GenBank U03780) [ka]

[0067] IgG3 (GenBank ABY85810.1) [ka]

[0068] IgG4a (GenBank AAA52220.1) [ka]

[0069] IgG4b (GenBank ABY85806.1) [ka]

[0070] IgG5a (GenBank ABY85809.1) [ka]

[0071] IgG5b (GenBank AB699687) [ka]

[0072] IgG6a (GenBank AB699687) [ka]

[0073] IgG6b (GenBank ABY85805.1) [ka]

[0074] The CH2 region of a porcine antibody contains or consists of amino acids 231–340 (according to EU numbering) of a porcine IgG antibody. It is understood that the CH2 region may contain 1–6 (e.g., 1, 2, 3, 4, 5, 6) additional amino acids or deletions at its N-terminus and / or C-terminus.

[0075] The CH3 region of a porcine antibody contains or consists of amino acids 341–447 (according to EU numbering) of a porcine IgG antibody. It is understood that the CH3 region may contain 1–6 (e.g., 1, 2, 3, 4, 5, 6) additional amino acids or deletions at its N-terminus and / or C-terminus.

[0076] The Fc region of a porcine IgG antibody contains or consists of amino acids 231-447 (according to EU numbering).

[0077] Table 1 below compares the amino acid sequences of the CH2 and CH3 domains of human IgG1, canine IgGB, and feline IgG1a with those of 11 porcine IgG isotypes based on their EU numbering: [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6]

[0078] Substitution of porcine IgG Fc to improve half-life Increased serum persistence is a beneficial property for therapeutic polypeptides. This disclosure features substitutions of the Fc regions of wild-type porcine IgG1a, IgG1b, IgG2a, IgG2b, IgG3, IgG4a, IgG4b, IgG5a, IgG5b, IgG6a, and IgG6b, the substitutions improving the half-life in porcine of one or more polypeptides containing these Fc regions compared to one or more control polypeptides, where one or more control polypeptides are identical to one or more polypeptides except that they have the Fc region of the corresponding wild-type porcine IgG instead of the Fc region variant of IgG. Substitutions that increase half-life may be made in association with one or more porcine CH2 regions, porcine CH3 regions, or porcine Fc (e.g., CH2+CH3) regions.

[0079] This disclosure relates to a polypeptide comprising a porcine IgG Fc region variant or a porcine FcRn binding region thereof, wherein the polypeptide has an amino acid substitution at at least one position selected from the group consisting of (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11): (i) A position corresponding to amino acid position 250 of wild-type porcine IgG, wherein the amino acid substitution is selected from the group consisting of T250Q, T250E, I250Q, and I250E; (ii) A position corresponding to amino acid position 252 of wild-type porcine IgG, wherein the amino acid substitution is selected from the group consisting of M252Y, M252W, and M252F; (iii) A position corresponding to amino acid position 254 of wild-type porcine IgG, wherein the amino acid substitution is selected from the group consisting of S254T, S254R, S254K, and S254H; (iv) A position corresponding to amino acid position 256 of wild-type porcine IgG, wherein the amino acid substitution is selected from the group consisting of T256A, T256D, and T256E; (v) A position corresponding to amino acid position 286 of wild-type porcine IgG, wherein the amino acid substitution is selected from the group consisting of T286Y, T286F, T286W, T286L, T286D, and T286E; (vi) A position corresponding to amino acid position 309 of wild-type porcine IgG, wherein the amino acid substitution is selected from the group consisting of Q309V, Q309D, and Q309E; (vii) A position corresponding to amino acid position 311 of wild-type porcine IgG, wherein the amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, Q311H, E311V, E311K, E311R, E311L, and E311H; (viii) A position corresponding to amino acid position 426 of wild-type porcine IgG, wherein the amino acid substitution is selected from the group consisting of A426Y, A426F, A426H, V426Y, V426F, and V426H; (ix) A position corresponding to amino acid position 428 of wild-type porcine IgG, wherein the amino acid substitution is selected from the group consisting of M428L, M428Y, M428F, H428L, H428Y, and H428F; (x) A position corresponding to amino acid position 434 of wild-type porcine IgG, wherein the amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W, N434Y, H434A, H434F, H434S, H434W, and H434Y; and (xi) The position corresponding to amino acid position 436 of wild-type porcine IgG, wherein the amino acid substitution is selected from the group consisting of Y436H and T436H, Here, based on EU numbering, the amino acid positions provide a polypeptide with increased binding affinity to bovine FcRn compared to the Fc domain of wild-type porcine IgG.

[0080] In some embodiments, the polypeptide includes amino acid substitutions at at least one position (e.g., 1, 2, 3, 4, 5, 6, or 7) selected from the group consisting of: (i) The position corresponding to amino acid position 252 of wild-type IgG in domestic animals, where the amino acid substitution is M252Y; (ii) The position corresponding to amino acid position 286 of wild-type IgG in domestic animals, wherein the amino acid substitution is T286E; (iii) A position corresponding to amino acid position 309 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q309D or Q309V; (iv) A position corresponding to amino acid position 311 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q311V; (v) The position corresponding to amino acid position 426 of wild-type IgG in domestic animals, wherein the amino acid substitution is A426Y; (vi) The position corresponding to amino acid position 428 of wild-type IgG in domestic animals, wherein the amino acid substitution is M428Y; and (vii) A position corresponding to amino acid position 434 of wild-type IgG of a domestic animal, wherein the amino acid substitution is selected from the group consisting of N434Y.

[0081] In some embodiments, the polypeptide exhibits increased binding affinity to porcine FcRn at pH approximately 5.0–6.5 (e.g., approximately 5.5 or approximately 6.0) compared to the Fc domain of wild-type porcine IgG at the same pH.

[0082] In some embodiments, the polypeptide comprises an amino acid sequence that is at least 80% (e.g., at least 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 11.

[0083] In some cases, the Disclosure provides CH2 domain variants of porcine IgG containing an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the CH2 domain shown in any one of SEQ ID NOs: 1 to 11. The Disclosure also provides CH2 domain variants of porcine IgG containing an amino acid sequence that differs by 1 to 15 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) from any one of the CH2 domains shown in SEQ ID NOs: 1 to 11.

[0084] In some cases, the Disclosure features CH3 domain variants of porcine IgG that include an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, or at least 98% or at least 99% identical to the CH3 domain amino acid sequence shown in any one of SEQ ID NOs: 1 to 11. The Disclosure also features CH3 domain variants of porcine IgG that include an amino acid sequence that differs by 1 to 15 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) from any one of the CH3 domain sequences shown in any one of SEQ ID NOs: 1 to 11.

[0085] In some cases, the Disclosure features Fc region variants of porcine IgG containing amino acid sequences that are at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequences described in any one of SEQ ID NOs: 1 to 11. Also disclosed are Fc region variants of porcine IgG containing amino acid sequences that differ by 1 to 20 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) from any one of SEQ ID NOs: 1 to 11.

[0086] In some embodiments, one or more polypeptides comprising a porcine IgG Fc CH2 domain variant are provided, wherein the CH2 domain variant comprises an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the CH2 domain shown in any one of SEQ ID NOs: 1 to 11.

[0087] In some embodiments, the polypeptides are characterized by one or more polypeptides comprising a porcine IgG Fc CH3 domain variant, wherein the CH3 domain variant comprises an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the CH3 domain shown in any one of SEQ ID NOs: 1 to 11.

[0088] In some embodiments, the polypeptide comprises one or more polypeptides containing an Fc region variant of porcine IgG, wherein the Fc region variant comprises an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence described in any one of SEQ ID NOs: 1 to 11.

[0089] Bovine antibodies Cattle typically possess three IgG heavy chains, known as IgG1, IgG2, and IgG3. These heavy chains represent three distinct subclasses of bovine IgG. The amino acid and DNA sequences of these heavy chains are available from the GENBANK database. Exemplary examples of the amino acid sequences of the CH2 and CH3 domains in the Fc region of the three bovine IgG heavy chains are shown below (the CH2 domain is underlined), along with the GenBank accession number (amino acid sequence or the mRNA sequence from which the amino acid sequence originates) for each heavy chain Fc region:

[0090] Bos Taurus IgG1 (GenBank ABE68619.1) [ka]

[0091] IgG2 (GenBank AQT27057.1) [ka]

[0092] IgG3 (GenBank AAC48761.1) [ka]

[0093] The CH2 region of a bovine antibody contains or consists of amino acids 231–340 (according to EU numbering) of a bovine IgG antibody. It is understood that the CH2 region may contain 1–6 (e.g., 1, 2, 3, 4, 5, 6) additional amino acids or deletions at its N-terminus and / or C-terminus.

[0094] The CH3 region of a bovine antibody contains or consists of amino acids 341–447 (according to EU numbering) of a bovine IgG antibody. It is understood that the CH3 region may contain 1–6 (e.g., 1, 2, 3, 4, 5, 6) additional amino acids or deletions at its N-terminus and / or C-terminus.

[0095] The Fc region of bovine IgG antibodies contains or consists of amino acids 231-447 (according to EU numbering).

[0096] Table 2 below compares the amino acid sequences of the CH2 and CH3 domains of human IgG1, canine IgGB, and feline IgG1a with those of the three bovine IgG isotypes based on their EU numbering: [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6]

[0097] Substitution of bovine IgG Fc to improve half-life Increased serum persistence is a beneficial property for therapeutic polypeptides. This disclosure features substitutions of the Fc regions of wild-type bovine IgG1, IgG2, and IgG3, the substitutions improving the bovine half-life of one or more polypeptides containing these Fc regions compared to one or more control polypeptides, where one or more control polypeptides are identical to one or more polypeptides except that they have the Fc region of the corresponding wild-type bovine IgG instead of the Fc region variant of IgG. Substitutions that increase half-life may be made in association with one or more bovine CH2 domains, bovine CH3 domains, or bovine Fc (e.g., CH2+CH3) regions.

[0098] This disclosure relates to a polypeptide comprising a bovine IgG Fc region variant or its bovine FcRn binding region, wherein the polypeptide has an amino acid substitution at at least one position selected from the group consisting of (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11): (i) A position corresponding to amino acid position 250 of wild-type bovine IgG, wherein the amino acid substitution is selected from the group consisting of T250Q and T250E; (ii) A position corresponding to amino acid position 252 of wild-type bovine IgG, wherein the amino acid substitution is selected from the group consisting of M252Y, M252W, M252F, T252Y, T252W, and T252F; (iii) A position corresponding to amino acid position 254 of wild-type bovine IgG, wherein the amino acid substitution is selected from the group consisting of S254T, S254R, S254K, S254H, T254R, T254K, and T254H; (iv) A position corresponding to amino acid position 256 of wild-type bovine IgG, wherein the amino acid substitution is selected from the group consisting of T256A, T256D, and T256E; (v) A position corresponding to amino acid position 286 of wild-type bovine IgG, wherein the amino acid substitution is selected from the group consisting of T286Y, T286F, T286W, T286L, T286D, and T286E; (vi) A position corresponding to amino acid position 309 of wild-type bovine IgG, wherein the amino acid substitution is selected from the group consisting of Q309V, Q309D, and Q309E; (vii) A position corresponding to amino acid position 311 of wild-type bovine IgG, wherein the amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, and Q311H; (viii) A position corresponding to amino acid position 426 of wild-type bovine IgG, wherein the amino acid substitution is selected from the group consisting of A426Y, A426F, A426H, V426Y, V426F, and V426H; (ix) A position corresponding to amino acid position 434 of wild-type bovine IgG, wherein the amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W and N434Y; and (x) The position corresponding to amino acid position 436 of wild-type bovine IgG, where the amino acid substitution is Y436H, is included. Here, based on EU numbering, the amino acid positions provide a polypeptide with increased binding affinity to bovine FcRn compared to the Fc domain of wild-type bovine IgG.

[0099] In some embodiments, the polypeptide includes amino acid substitutions at at least one position (e.g., 1, 2, 3, 4, or 5) selected from the group consisting of: (i) The position corresponding to amino acid position 252 of wild-type IgG in domestic animals, where the amino acid substitution is T252Y; (ii) The position corresponding to amino acid position 309 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q309V; (iii) A position corresponding to amino acid position 311 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q311V; (iv) A position corresponding to amino acid position 434 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of N434Y; (v) A position corresponding to amino acid position 436 of wild-type IgG of livestock animals, wherein the amino acid substitution is selected from the group consisting of Y436H.

[0100] In some embodiments, the polypeptide exhibits increased binding affinity to bovine FcRn at pH approximately 5.0–6.5 (e.g., approximately 5.5 or approximately 6.0) compared to the Fc domain of wild-type bovine IgG at the same pH.

[0101] In some embodiments, the polypeptide comprises an amino acid sequence that is at least 80% (e.g., at least 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs. 12-14.

[0102] In some cases, the Disclosure provides CH2 domain variants of bovine IgG that include an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the CH2 domain shown in any one of SEQ ID NOs. The Disclosure also provides CH2 domain variants of bovine IgG that include an amino acid sequence that differs by 1 to 15 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) from any one of the CH2 domains shown in SEQ ID NOs.

[0103] In other cases, the Disclosure features CH3 domain variants of bovine IgG comprising an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the CH3 domain amino acid sequence shown in any one of SEQ ID NOs: 12-14. The Disclosure also features CH3 domain variants of bovine IgG comprising an amino acid sequence that differs by 1 to 15 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) from any one of the CH3 domain sequences shown in any one of SEQ ID NOs: 12-14.

[0104] In certain cases, the Disclosure features Fc region variants of bovine IgG that include an amino acid sequence identical by at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% to the amino acid sequence described in any one of SEQ ID NOs. The Disclosure also discloses Fc region variants of bovine IgG that include an amino acid sequence that differs by 1 to 20 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) from any one of SEQ ID NOs.

[0105] In some embodiments, one or more polypeptides comprising a bovine IgG Fc CH2 domain variant are provided, wherein the CH2 domain variant comprises an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the CH2 domain shown in any one of SEQ ID NOs. 12-14.

[0106] In some embodiments, the polypeptides are characterized by one or more polypeptides comprising a bovine IgG Fc CH3 domain variant, wherein the CH3 domain variant comprises an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the CH3 domain shown in any one of SEQ ID NOs. 12-14.

[0107] In some embodiments, the polypeptide comprises one or more polypeptides containing an Fc region variant of bovine IgG, wherein the Fc region variant comprises an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence described in any one of SEQ ID NOs. 12-14.

[0108] Horse antibodies Horses typically possess seven IgG heavy chains, known as IgG1, IgG2, IgG3, IgG4, IgG5, IgG6, and IgG7. These heavy chains represent seven distinct subclasses of horse IgG. The amino acid and DNA sequences of these heavy chains are available from the GENBANK database. Illustrative examples of the amino acid sequences of the CH2 and CH3 domains of the Fc region of the seven horse IgG heavy chains are shown below (the CH2 domain is underlined), along with the GenBank accession number (amino acid sequence or the mRNA sequence from which the amino acid sequence originates) for each heavy chain Fc region:

[0109] Horse (Equus caballus) IgG1 (GenBank CAC44760.1) [ka]

[0110] IgG2 (GenBank CAC44761.1) [ka]

[0111] IgG3 (GenBank AAP82181.1) [ka]

[0112] IgG4 (GenBank AAS18415.1) [ka]

[0113] IgG5 (GenBank CAC86340.1) [ka]

[0114] IgG6 (GenBank CAC86341.1) [ka]

[0115] IgG7 (GenBank AAS18414.1) [ka]

[0116] The CH2 region of a horse antibody contains or consists of amino acids 231–340 (according to EU numbering) of the horse IgG antibody. It is understood that the CH2 region may contain 1–6 (e.g., 1, 2, 3, 4, 5, 6) additional amino acids or deletions at its N-terminus and / or C-terminus.

[0117] The CH3 region of a horse antibody contains or consists of amino acids 341–447 (according to EU numbering) of the horse IgG antibody. It is understood that the CH3 region may contain 1–6 (e.g., 1, 2, 3, 4, 5, 6) additional amino acids or deletions at its N-terminus and / or C-terminus.

[0118] The Fc region of the horse IgG antibody contains or consists of amino acids 231-447 (according to EU numbering).

[0119] Table 3 below compares the amino acid sequences of the CH2 and CH3 domains of human IgG1, canine IgGB, and feline IgG1a with those of seven equine IgG isotypes based on their EU numbering: [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6]

[0120] Substitution of horse IgG Fc to improve half-life Increased persistence in serum is a beneficial property for therapeutic polypeptides. The present disclosure features substitutions in the Fc regions of wild-type equine IgG1, IgG2, IgG3, IgG4, IgG5, IgG6, and IgG7, which substitutions improve the half-life in horses of one or more polypeptides comprising these Fc regions compared to one or more control polypeptides, where the one or more control polypeptides are identical to the one or more polypeptides except having the Fc region of the corresponding wild-type equine IgG in place of the Fc region variant of IgG. Substitutions that increase the half-life can be made in one or more of the equine CH2 domain, the equine CH3 domain, or in relation to the equine Fc (e.g., CH2 + CH3) region.

[0121] The present disclosure is a polypeptide comprising an Fc region variant of equine IgG or its equine FcRn binding region, wherein the polypeptide has an amino acid substitution at at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11) position selected from the group consisting of: (i) the position corresponding to amino acid position 250 of wild-type equine IgG, wherein the amino acid substitution is selected from the group consisting of T250Q, T250E, A250Q, A250E, V250Q, and V250E; (ii) the position corresponding to amino acid position 252 of wild-type equine IgG, wherein the amino acid substitution is selected from the group consisting of M252Y, M252W, M252F, K252Y, K252W, and K252F; (iii) the position corresponding to amino acid position 254 of wild-type equine IgG, wherein the amino acid substitution is selected from the group consisting of S254T, S254R, S254K, S254H, T254R, T254K, and T254H; (iv) the position corresponding to amino acid position 256 of wild-type equine IgG, wherein the amino acid substitution is selected from the group consisting of T256A, T256D, T256E, M256A, M256D, M256E, K256A, K256D, and K256E; (v) A position corresponding to amino acid position 286 of wild-type equine IgG, wherein the amino acid substitution is selected from the group consisting of S286Y, S286F, S286W, S286L, S286D, S286E, T286Y, T286F, T286W, T286L, T286D and T286E; (vi) A position corresponding to amino acid position 309 of wild-type equine IgG, wherein the amino acid substitution is selected from the group consisting of Q309V, Q309D and Q309E; (vii) A position corresponding to amino acid position 311 of wild-type equine IgG, wherein the amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, Q311H, K311V, K311R, K311L and K311H; (viii) A position corresponding to amino acid position 426 of wild-type equine IgG, wherein the amino acid substitution is selected from the group consisting of A426Y, A426F, A426H, V426Y, V426F, V426H, G426Y, G426F and G426H; (ix) A position corresponding to amino acid position 428 of wild-type equine IgG, wherein the amino acid substitution is selected from the group consisting of M428L, M428Y and M428F; (x) A position corresponding to amino acid position 434 of wild-type equine IgG, wherein the amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W, N434Y, H434A, H434F, H434S, H434W and H434Y; and (xi) A position corresponding to amino acid position 436 of wild-type equine IgG, wherein the amino acid substitution is selected from the group consisting of Y436H, F436H and V436H, wherein the amino acid positions are based on EU numbering, and the polypeptide provides a polypeptide having an increased binding affinity for equine FcRn when compared to the Fc domain of wild-type equine IgG.

[0122] In some embodiments, the polypeptide contains amino acid substitutions at at least one position (e.g., 1, 2, 3, 4, 5, or 6) selected from the group consisting of: (i) The position corresponding to amino acid position 252 of wild-type IgG in domestic animals, where the amino acid substitution is M252Y; (ii) The position corresponding to amino acid position 286 of wild-type IgG in domestic animals, wherein the amino acid substitution is T286E; (iii) A position corresponding to amino acid position 309 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q309V; (iv) A position corresponding to amino acid position 311 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q311V; (v) The position corresponding to amino acid position 426 of wild-type IgG in domestic animals, where the amino acid substitution is G426Y; (vi) A position corresponding to amino acid position 434 of wild-type IgG of a domestic animal, wherein the amino acid substitution is selected from the group consisting of N434Y.

[0123] In some embodiments, the polypeptide exhibits increased binding affinity to horse FcRn at pH approximately 5.0–6.5 (e.g., approximately 5.5 or approximately 6.0) compared to the Fc domain of wild-type horse IgG at the same pH.

[0124] In some embodiments, the polypeptide comprises an amino acid sequence that is at least 80% (e.g., at least 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs. 15 to 21.

[0125] In some cases, the Disclosure provides CH2 domain variants of horse IgG that include an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the CH2 domain shown in any one of SEQ ID NOs. The Disclosure also provides CH2 domain variants of horse IgG that include an amino acid sequence that differs by 1 to 15 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) from any one of the CH2 domains shown in SEQ ID NOs.

[0126] In some cases, the Disclosure features CH3 domain variants of horse IgG that include an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, or at least 98% or at least 99% identical to the CH3 domain amino acid sequence shown in any one of SEQ ID NOs: 15-21. The Disclosure also features CH3 domain variants of horse IgG that include an amino acid sequence that differs by 1 to 15 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) from any one of the CH3 domain sequences shown in any one of SEQ ID NOs: 15-21.

[0127] In some cases, the Disclosure features Fc region variants of horse IgG that include an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence described in any one of SEQ ID NOs. The Disclosure also discloses Fc region variants of horse IgG that include an amino acid sequence that differs by 1 to 20 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) from any one of SEQ ID NOs.

[0128] In some embodiments, one or more polypeptides comprising a horse IgG Fc CH2 domain variant are provided, wherein the CH2 domain variant comprises an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the CH2 domain shown in any one of SEQ ID NOs. 15-21.

[0129] In some embodiments, the polypeptides are characterized by one or more polypeptides comprising an Fc CH3 domain variant of horse IgG, wherein the CH3 domain variant comprises an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the CH3 domain shown in any one of SEQ ID NOs. 15-21.

[0130] In some embodiments, the polypeptide is characterized by one or more polypeptides comprising an Fc region variant of horse IgG, wherein the Fc region variant comprises an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence described in any one of SEQ ID NOs. 15 to 21.

[0131] Sheep antibodies Sheep typically have three IgG heavy chains called IgG1, IgG2, and IgG3. These heavy chains represent three different sheep IgG subclasses. The amino acid and DNA sequences of these heavy chains are available from the GENBANK database. Exemplary examples of the amino acid sequences of the CH2 and CH3 domains of each of the Fc regions of the three sheep IgG heavy chains are shown below (underlining the CH2 domain), showing the GenBank accession numbers (amino acid sequences or the mRNA sequences from which the amino acid sequences are derived) of each heavy chain Fc region:

[0132] Sheep Oviari

Chemical formula

[0133] IgG2 (Genbank X70983)

Chemical formula

[0134] IgG3 (Schwartz et al, 2018, Immunogenetics, 70:317)

Chemical formula

[0135] The CH2 region of a sheep antibody contains, or consists of, amino acids 231 - 340 (according to EU numbering) of a sheep IgG antibody. It is understood that the CH2 region may contain, at its N-terminus and / or C-terminus, 1 - 6 additional amino acids or deletions (for example, 1, 2, 3, 4, 5, 6 amino acids).

[0136] The CH3 region of a sheep antibody contains, or consists of, amino acids 341 - 447 (according to EU numbering) of a sheep IgG antibody. It is understood that the CH3 region may contain, at its N-terminus and / or C-terminus, 1 - 6 additional amino acids or deletions (for example, 1, 2, 3, 4, 5, 6 amino acids).

[0137] The Fc region of the sheep IgG antibody contains or consists of amino acids 231-447 (according to EU numbering).

[0138] Table 4 below compares the amino acid sequences of the CH2 and CH3 domains of human IgG1, canine IgGB, and feline IgG1a with those of the three sheep IgG isotypes, based on their EU numbering: [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] [Table 4-6]

[0139] Substitution of sheep IgG Fc to improve half-life Increased serum persistence is a beneficial property for therapeutic polypeptides. This disclosure features substitutions of the Fc regions of wild-type sheep IgG1, IgG2, and IgG3, the substitutions improving the half-life in sheep of one or more polypeptides containing these Fc regions compared to one or more control polypeptides, where one or more control polypeptides are identical to one or more polypeptides except that they have the Fc region of the corresponding wild-type sheep IgG instead of the Fc region variant of IgG. Substitutions that increase half-life may be made in association with one or more sheep CH2 domains, sheep CH3 domains, or sheep Fc (e.g., CH2+CH3) regions.

[0140] This disclosure relates to a polypeptide comprising a sheep IgG Fc region variant or its sheep FcRn binding region, wherein the polypeptide has an amino acid substitution at at least one position selected from the group consisting of (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11): (i) A position corresponding to amino acid position 250 of wild-type sheep IgG, wherein the amino acid substitution is selected from the group consisting of S250Q, S250E, T250Q, and T250E; (ii) A position corresponding to amino acid position 252 of wild-type sheep IgG, wherein the amino acid substitution is selected from the group consisting of M252Y, M252W, M252F, T252Y, T252W, and T252F; (iii) A position corresponding to amino acid position 254 of wild-type sheep IgG, wherein the amino acid substitution is selected from the group consisting of S254R, S254K, S254H, T254R, T254K, and T254H; (iv) A position corresponding to amino acid position 256 of wild-type sheep IgG, wherein the amino acid substitution is selected from the group consisting of T256A, T256D, and T256E; (v) A position corresponding to amino acid position 286 of wild-type sheep IgG, wherein the amino acid substitution is selected from the group consisting of T286Y, T286F, T286W, T286L, T286D, and T286E; (vi) A position corresponding to amino acid position 309 of wild-type sheep IgG, wherein the amino acid substitution is selected from the group consisting of Q309V, Q309D, and Q309E; (vii) A position corresponding to amino acid position 311 of wild-type sheep IgG, wherein the amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, Q311H, D311V, D311K, D311R, D311L, and D311H; (viii) A position corresponding to amino acid position 426 of wild-type sheep IgG, wherein the amino acid substitution is selected from the group consisting of V426Y, V426F, and V426H; (ix) A position corresponding to amino acid position 428 of wild-type sheep IgG, wherein the amino acid substitution is selected from the group consisting of M428L, M428Y, and M428F; (x) A position corresponding to amino acid position 434 of wild-type sheep IgG, wherein the amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W and N434Y; and (xi) The position corresponding to amino acid position 436 of wild-type sheep IgG, and the amino acid substitution is Y436H, Here, based on EU numbering, the amino acid positions provide a polypeptide with increased binding affinity to sheep FcRn compared to the Fc domain of wild-type sheep IgG.

[0141] In some embodiments, the polypeptide includes amino acid substitutions at at least one position (e.g., 1, 2, 3, 4, or 5) selected from the group consisting of: (i) The position corresponding to amino acid position 252 of wild-type IgG in domestic animals, where the amino acid substitution is T252Y; (ii) The position corresponding to amino acid position 309 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q309V; (iii) A position corresponding to amino acid position 311 of wild-type IgG in domestic animals, wherein the amino acid substitution is Q311V; (iv) A position corresponding to amino acid position 428 of wild-type IgG of domestic animals, wherein the amino acid substitution is selected from the group consisting of M428Y; (v) A position corresponding to amino acid position 434 of wild-type IgG of a domestic animal, wherein the amino acid substitution is selected from the group consisting of N434Y.

[0142] In some embodiments, the polypeptide exhibits increased binding affinity to sheep FcRn at pH approximately 5.0–6.5 (e.g., approximately 5.5 or approximately 6.0) compared to the Fc domain of wild-type sheep IgG at the same pH.

[0143] In some embodiments, the polypeptide comprises an amino acid sequence that is at least 80% (e.g., at least 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs. 22-24.

[0144] In some cases, the Disclosure provides CH2 domain variants of sheep IgG that include an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the CH2 domain shown in any one of SEQ ID NOs. The Disclosure also provides CH2 domain variants of sheep IgG that include an amino acid sequence that differs by 1 to 15 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) from any one of the CH2 domains shown in SEQ ID NOs.

[0145] In some cases, the Disclosure features CH3 domain variants of sheep IgG that include an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, or at least 98% or at least 99% identical to the CH3 domain amino acid sequence shown in any one of SEQ ID NOs.22-24. The Disclosure also features CH3 domain variants of sheep IgG that include an amino acid sequence that differs by 1 to 15 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) from any one of the CH3 domain sequences shown in any one of SEQ ID NOs.

[0146] In some cases, the Disclosure features Fc region variants of sheep IgG that include an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence described in any one of SEQ ID NOs.22-24. The Disclosure also discloses Fc region variants of sheep IgG that include an amino acid sequence that differs by 1 to 20 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) from any one of SEQ ID NOs.

[0147] In some embodiments, one or more polypeptides are provided that contain a sheep IgG Fc CH2 domain variant, the CH2 domain variant comprising an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the CH2 domain shown in any one of SEQ ID NOs. 22-24.

[0148] In some embodiments, the polypeptides are characterized by one or more polypeptides comprising a sheep IgG Fc CH3 domain variant, wherein the CH3 domain variant comprises an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the CH3 domain shown in any one of SEQ ID NOs. 22-24.

[0149] In some embodiments, the polypeptides are characterized by one or more polypeptides comprising an Fc region variant of sheep IgG, wherein the Fc region variant comprises an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence described in any one of SEQ ID NOs. 22-24.

[0150] Goat antibodies Goats typically possess three IgG heavy chains, known as IgG1, IgG2, and IgG3. These heavy chains represent three distinct subclasses of goat IgG. The amino acid and DNA sequences of these heavy chains are available from the GENBANK database. Exemplary examples of the amino acid sequences of the CH2 and CH3 domains in the Fc region of the three goat IgG heavy chains are shown below (the CH2 domain is underlined):

[0151] goat (Capra hircus) IgG1 (Schwartz et al, 2018, Immunogenetics, 70:317) [ka]

[0152] IgG2 (Schwartz et al, 2018, Immunogenetics, 70:317) [ka]

[0153] IgG3 (Schwartz et al, 2018, Immunogenetics, 70:317) [ka]

[0154] The CH2 region of goat antibodies contains or consists of amino acids 231–340 (according to EU numbering). It is understood that the CH2 region may contain 1–6 (e.g., 1, 2, 3, 4, 5, 6) additional amino acids or deletions at its N-terminus and / or C-terminus.

[0155] The CH3 region of goat antibodies contains or consists of amino acids 341–447 (according to EU numbering) of goat IgG antibodies. It is understood that the CH3 region may contain 1–6 (e.g., 1, 2, 3, 4, 5, 6) additional amino acids or deletions at its N-terminus and / or C-terminus.

[0156] The Fc region of the goat IgG antibody contains or consists of amino acids 231-447 (according to EU numbering).

[0157] Table 5 below compares the amino acid sequences of the CH2 and CH3 domains of human IgG1, canine IgGB, and feline IgG1a with those of the three goat IgG isotypes, based on their EU numbering: [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 5-6]

[0158] Substitution of goat IgG Fc to improve half-life Increased serum persistence is a beneficial property for therapeutic polypeptides. This disclosure features substitutions of the Fc regions of wild-type goat IgG1, IgG2, and IgG3, the substitutions improving the half-life in goats of one or more polypeptides containing these Fc regions compared to one or more control polypeptides, where one or more control polypeptides are identical to one or more polypeptides except that they have the Fc region of the corresponding wild-type goat IgG instead of the Fc region variant of IgG. Substitutions that increase half-life may be made in association with one or more of the goat CH2 domain, goat CH3 domain, or goat Fc (e.g., CH2+CH3) regions.

[0159] This disclosure relates to a polypeptide comprising a goat IgG Fc region variant or a goat FcRn binding region thereof, wherein the polypeptide has an amino acid substitution at at least one position selected from the group consisting of (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11): (i) A position corresponding to amino acid position 250 of wild-type goat IgG, wherein the amino acid substitution is selected from the group consisting of S250Q, S250E, T250Q, and T250E; (ii) A position corresponding to amino acid position 252 of wild-type goat IgG, wherein the amino acid substitution is selected from the group consisting of M252Y, M252W, M252F, T252Y, T252W, and T252F; (iii) A position corresponding to amino acid position 254 of wild-type goat IgG, wherein the amino acid substitution is selected from the group consisting of S254R, S254K, S254H, T254R, T254K, and T254H; (iv) A position corresponding to amino acid position 256 of wild-type goat IgG, wherein the amino acid substitution is selected from the group consisting of T256A, T256D, T256E, K256A, K256D, and K256E; (v) A position corresponding to amino acid position 286 of wild-type goat IgG, wherein the amino acid substitution is selected from the group consisting of T286Y, T286F, T286W, T286L, T286D, and T286E; (vi) A position corresponding to amino acid position 309 of wild-type goat IgG, wherein the amino acid substitution is selected from the group consisting of Q309V, Q309D, and Q309E; (vii) A position corresponding to amino acid position 311 of wild-type goat IgG, wherein the amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, Q311H, K311V, K311R, K311L, K311H, D311V, D311K, D311R, D311L, and D311H; (viii) A position corresponding to amino acid position 426 of wild-type goat IgG, wherein the amino acid substitution is selected from the group consisting of A426Y, A426F, A426H, V426Y, V426F, and V426H; (ix) A position corresponding to amino acid position 428 of wild-type goat IgG, wherein the amino acid substitution is selected from the group consisting of M428L, M428Y, and M428F; (x) A position corresponding to amino acid position 434 of wild-type goat IgG, wherein the amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W and N434Y; and (xi) The position corresponding to amino acid position 436 of wild-type goat IgG, and the amino acid substitution is Y436H, Here, based on EU numbering, the amino acid positions provide a polypeptide with increased binding affinity to goat FcRn compared to the Fc domain of wild-type goat IgG.

[0160] In some embodiments, the polypeptide exhibits increased binding affinity to goat FcRn at pH approximately 5.0–6.5 (e.g., approximately 5.5 or approximately 6.0) compared to the Fc domain of wild-type goat IgG at the same pH.

[0161] In some embodiments, the polypeptide comprises an amino acid sequence that is at least 80% (e.g., at least 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs. 25-27.

[0162] In some cases, the Disclosure provides CH2 domain variants of goat IgG containing an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the CH2 domain shown in any one of SEQ ID NOs. The Disclosure also provides CH2 domain variants of goat IgG containing an amino acid sequence that differs by 1 to 15 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) from any one of the CH2 domains shown in SEQ ID NOs.

[0163] In some cases, the Disclosure features CH3 domain variants of goat IgG that include an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, or at least 98% or at least 99% identical to the CH3 domain amino acid sequence shown in any one of SEQ ID NOs.25-27. The Disclosure also features CH3 domain variants of goat IgG that include an amino acid sequence that differs by 1 to 15 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) from any one of the CH3 domain sequences shown in any one of SEQ ID NOs.

[0164] In some cases, the Disclosure features Fc region variants of goat IgG that include an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence described in any one of SEQ ID NOs.25-27. The Disclosure also discloses Fc region variants of goat IgG that include an amino acid sequence that differs by 1 to 20 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) from any one of SEQ ID NOs.

[0165] In some embodiments, one or more polypeptides comprising a goat IgG Fc CH2 domain variant are provided, wherein the CH2 domain variant comprises an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the CH2 domain shown in any one of SEQ ID NOs. 25-27.

[0166] In some embodiments, the polypeptides are characterized by one or more polypeptides comprising a goat IgG Fc CH3 domain variant, wherein the CH3 domain variant comprises an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the CH3 domain shown in any one of SEQ ID NOs. 25-27.

[0167] In some embodiments, the polypeptide is characterized by one or more polypeptides comprising an Fc region variant of goat IgG, wherein the Fc region variant comprises an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence described in any one of SEQ ID NOs. 25-27.

[0168] This disclosure extends to one or more polypeptides in which amino acid substitutions are made in either one or both of the CH2 and CH3 domains. In some cases, the substitutions on the CH2 and / or CH3 domains are identical. In some cases, the substitutions on the CH2 and / or CH3 domains are not identical. In some cases, the Fc region includes one or more additional substitutions that result in an increase or decrease in effector function and / or improvement of product heterogeneity.

[0169] Other substitutions that can be combined with substitutions that improve half-life The development of therapeutic polypeptides / proteins (e.g., monoclonal antibodies) is a complex process that requires the coordination of a series of intricate operations to produce the desired polypeptide / protein. These operations include optimizing specificity, affinity, functional activity, expression levels in artificial cell lines, long-term stability, removal or enhancement of effector functions, and the development of commercially viable manufacturing and purification methods. This disclosure encompasses any additional substitutions that facilitate one or more of the above objectives.

[0170] In some embodiments, substitutions are introduced into the Fc region of wild-type IgG in livestock animals to facilitate purification by protein A chromatography and to enhance binding to protein A. Such substitutions are known to those skilled in the art and can be at one or more positions (e.g., 1, 2, 3, 4, 5, 6, or 7) of IgG.

[0171] In some embodiments, additional amino acid substitutions are made to alter the binding affinity to FcRn compared to the parent polypeptide or wild-type polypeptide (e.g., to increase or decrease the binding affinity to FcRn).

[0172] In some embodiments, the polypeptide comprises the hinge region of an antibody of a livestock animal. In some embodiments, modifications can be made to the hinge region of the antibody of a livestock animal to increase its half-life. Such modifications are known to those skilled in the art.

[0173] polypeptide containing IgG Fc variant This disclosure encompasses any polypeptides that can benefit from increasing their half-life in livestock animals. To increase the half-life, these polypeptides are designed to include Fc region variants disclosed above (e.g., CH2 region, CH3 region, CH2+CH3 region).

[0174] Exemplary polypeptides include, but are not limited to, whole antibodies, scFv, nanobodies, ligand-binding moieties of receptors, cytokines, growth factors, enzymes, and peptides. For example, the CH3 domain variant disclosed above may be bound to scFv nanobodies, ligand-binding moieties of receptors (e.g., ligand-binding moieties of IL-13Rα1 or IL-13Rα2), cytokines, growth factors, enzymes, or peptides. As used herein, the terms “nanobody,” “VHH,” “VHH antibody fragment,” and “single-domain antibody” are used interchangeably herein to refer to the variable domain of a single heavy chain of antibodies of the type found in camelids, which are typically naturally occurring and lack a light chain. Preferred nanobodies are well known to those skilled in the art, and examples include nanobodies from camels, dromedaries, llamas, and alpacas. Alternatively, the Fc region variant disclosed above may be bound to these polypeptides. In another embodiment, antibodies derived from domestic animals are modified to include the Fc region variant disclosed herein.

[0175] In some embodiments, the polypeptides of this disclosure include an antibody hinge region. The hinge region may be positioned between the ligand-binding domain of the antigen or polypeptide and an Fc region variant. In some cases, the hinge region is bound to the C-terminus of a cytokine, growth factor, enzyme, or peptide, and the hinge region is bound to the N-terminus of an Fc region variant. Suitable hinge region sequences are known to those skilled in the art.

[0176] The hinge region in the polypeptides of this disclosure, when used, may contain 0 to 6 amino acid substitutions (i.e., 0, 1, 2, 3, 4, 5, or 6) compared to the amino acid sequence of the natural hinge region. In some cases, the hinge region used in the recombinant proteins of this disclosure is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of the natural hinge region.

[0177] One or more polypeptides of this disclosure may include a binding domain. The binding domain can specifically bind to a protein, subunit, domain, motif, and / or epitope of a select target as described herein. In some embodiments, one or more polypeptides (e.g., fusion polypeptides) may include a protein, where the protein is a therapeutic protein as described herein. In some embodiments, the target (e.g., the target of the binding domain) or the therapeutic protein (e.g., fusion polypeptide) is selected from the group consisting of: 17-IA, 4-1BB, 4Dc, 6-keto-PGF1a, 8-iso-PGF2a, 8-oxo-dG, A1 adenosine receptor, A33, ACE, ACE-2, activin, activin A, activin AB, activin B, activin C, activin RIA, activin RIA ALK-2, activin RIB ALK-4, activin RIIA, activin RIIB, ADAM, ADAM10, ADAM12, ADAM15, ADAM17 / TACE, ADAMS, ADAM9, ADAMTS, ADAMTS4, ADAMTS5, adresin, aFGF, ALCAM, ALK, ALK-1, ALK-7, alpha-1 antitrypsin, alpha-V / beta-1 antagonist, ANG, Ang, APAF-1, APE, APJ, APP, APRIL, AR, IgE, angiotensin type 1 (AT1) receptor, Angiotensin type 2 (AT2) receptor, ARC, ART, Artemin, Anti-Id, ASPARTIC, Atrial natriuretic factor, av / b3 integrin, Axl, b2M, B7-1, B7-2, B7-H, B lymphocyte-stimulating factor (BlyS), BACE, BACE-1, Bad, BAFF, BAFF-R, Bag-1, BAK, Bax, BCA-1, BCAM, Bcl, BCMA, BDNF, b-ECGF, bFGF, BID, Bik, BIM, BLC, BL-CAM, BLK, BMP, BMP-2, BMP-2a, BMP-3 osteogenin, BMP-4, BMP-2b, BMP-5, BMP-6Vgr-1, BMP-7 (OP-1), BMP-8 (BMP-8a, OP-2), BMPR, BMPR-IA (ALK-3), BMPR-IB (ALK-6), BRK-2, RPK-1, BMPR-II (BRK-3), BMPs, b-NGF, BOK, bombesin, bone-derived neurotrophic factor, BPDE, BPDE-DNA, BTC, complement factor 3 (C3), C3a, C4, C5, C5a, C10, CA125, CAD-8, calcitonin, cAMP, carcinoembryonic antigen (CEA), carcinoma-associated antigen, cathepsin A, cathepsin B, Cathepsin C / DPPI, Cathepsin D, Cathepsin E, Cathepsin H, Cathepsin L, Cathepsin O, Cathepsin S, Cathepsin V, Cathepsin X / Z / P, CBL, CC1, CCK2, CCL, CCL1, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CCL3, CCL4, CCL5, CCL6, CC L7, CCL8, CCL9 / 10, CCR, CCR1, CCR10, CCR10, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CD1, CD2, CD3, CD3E, CD4, CD5, CD6, CD7, CD8, C D10, CD11a, CD11b, CD11c, CD13, CD14, CD15, CD16, CD18, CD19, CD20, CD21, CD22, CD23, CD25, CD27L, CD28, CD29, CD30, CD30L, CD32, CD33(p6 7 proteins), CD34, CD38, CD40, CD40L, CD44, CD45, CD46, CD47, CD49a, CD52, CD54, CD55, CD56, CD61, CD64, CD66e, CD74, CD80(B7-1), CD89, CD95, CD123, CD137, CD138, CD140a, CD146, CD147, CD148, CD152, CD164, CEACAM5, CFTR, cGMP, CINC, botulinum toxin, Clostridium perfringens toxin, CKb8-1, CLC, CMV, CMVUL, CNTF, CNTN-1, COX, C-Ret, CRG-2, CT-1, CTACK, CTGF, CTLA-4, CX3CL1, CX3CR1, CXCL, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7 , CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCR, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, cytokeratin tumor-related Antigen, DAN, DCC, DcR3, DC-SIGN, Degradation Promoter, des(1-3)-IGF-I (brain IGF-1), Dhh, Digoxin, DNAM-1, Dnase, Dpp, DPPIV / CD26, Dtk, ECAD, EDA, EDA-A1, EDA-A2, EDAR, EGF, EGFR (ErbB-1), EMA, EMMPRIN, ENA, Endothelin Receptor, Enkephalinase, eNOS, Eot, Eotaxin 1, EpCAM, Ephrin B2 / EphB4, EPO, ERCC, E-Selecti N, ET-1, Factor IIa, Factor VII, Factor VIIIc, Factor IX, Fibroblast-Activating Protein (FAP), Fas, FcR1, FEN-1, Ferritin, FGF, FGF-19, FGF-2, FGF3, FGF-8, FGFR, FGFR-3, Fibrin, FL, FLIP, Flt-3, Flt-4, Follicle-Stimulating Hormone, Fractalkine, FZD1, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9, FZD10, G250, Gas6, GCP-2, G CSF, GD2, GD3, GDF, GDF-1, GDF-3 (Vgr-2), GDF-5 (BMP-14, CDMP-1), GDF-6 (BMP-13, CDMP-2), GDF-7 (BMP-12, CDMP-3), GDF-8 (Myostatin), GDF-9, GDF-15 (MIC-1), GDNF, GDNF, GFAP, GFRa-1, GFR-Alpha 1, GFR-Alpha 2, GFR-Alpha 3, GITR, GLP1, GLP2, Glucagon, Glut4, Glycoprotein IIb / IIIa (GP IIb / IIIa), GM-CSF, gp130, gp72, GRO, GnRH, Growth hormone-releasing factor, Hapten (NP-cap or NIP-cap), HB-EGF, HCC, HCMVgB envelope glycoprotein, HCMV) gH envelope glycoprotein, HCMV UL, hematopoietic growth factor (HGF), Hep B gp120, heparanase, Her2, Her2 / neu (ErbB-2), Her3 (ErbB-3), Her4 (ErbB-4), herpes simplex virus (HSV) gB glycoprotein, HSV gD glycoprotein, HGFA, high molecular weight melanoma-associated antigen (HMW-MAA), HIV gp120, HIV IIIB gp120 V3 loop, HLA, HLA-DR, HM1.24, HMFGPEM, HRG, Hrk, cardiac myosin, cytomegalovirus (CMV), growth hormone (GH), HVEM, 1-309, IAP, ICAM, ICAM-1, ICAM-3, ICE, ICOS, IFNg, Ig, IgA receptor, IgE, IGF, IGF-binding protein, IGF-1R, IGFBP, IGF-I, IGF-II, IL, IL-1, IL-1R, IL-2, IL-2R, IL-4, IL-4R, IL-5, IL-5R, IL-6, IL-6R, IL-8, IL- 9, IL-10, IL-12, IL-13, IL-15, IL-17, IL-18, IL-18R, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, interleukin receptors (e.g., IL-1R, IL-2 R, IL-4R, IL-5R, IL-6R, IL-8R, IL-9R, IL-10R, IL-12R, IL-13R, IL-15R, IL-17R, IL-18R, IL-21R, IL-22R, IL-23R, IL-25R, IL-31R IL-33R), interferon (INF)-alpha, INF-beta, INF-gamma, inhibin, iNOS, insulin A chain, insulin B chain, insulin-like growth factor 1, integrin alpha 2, integrin alpha 3, integrin alpha 4, integrin alpha 4 / beta 1, integrin alpha 4 / beta 7, integrin alpha 5 (alpha V), integrin alpha 5 / beta 1, integrin alpha 5 / beta 3, integrin alpha A6, Integrin Beta 1, Integrin Beta 2, Interferon Gamma, IP-10, I-TAC, JE, Kallikrein 2, Kallikrein 5, Kallikrein 6, Kallikrein 11, Kallikrein 12, Kallikrein 14, Kallikrein 15, Kallikrein L1, Kallikrein L2, Kallikrein L3, Kallikrein L4, KC, KDR, Keratinocyte Growth Factor (KGF), Laminin 5, LAMP, LAP, LAP(TGF-1), Latent TGF-1, Latent TGF-1bp1, LBP, LDGF, LECT2, Lefty, Lewis Y antigen, Lewis Y-related antigen, LFA-1, LFA-3, Lfo, LIF, LIGHT, lipoprotein, LIX, LKN, Lptn, L-selectin, LT-a, LT-b, LTB4, LTBP-1, pulmonary surfactant, luteinizing hormone, lymphotoxin beta receptor, Mac-1, MAdCAM, MAG, MAP2, MARC, MCAM, MCAM, MCK-2, MCP, M-CSF, MDC, Mer, metalloproteinase, MGDF receptor, MGMT, MHC (HLA-DR), MIF, MIG, MIP, MIP-1-alpha, MK, MMAC1, MMP, MMP-1, MMP-10, MMP-11, MMP-12, MMP-13, MMP-14, MMP-15, MMP-2, MMP-24, MMP-3, MMP-7, MMP-8, MMP-9, MPIF, Mpo, MSK, MSP, mucin (Muc1), MUC18, Müllerian duct inhibitor, Mug, MuSK, NAIP, NAP, NAV1.7, NCAD, N-C Doherin, NCA90, NCAM, Neprilysin, Neurotrophin-3, -4, or -6, Neuroturin, Nerve Growth Factor (NGF), NGFR, NGF-Beta, nNOS, NO, NOS, Npn, NRG-3, NT, NTN, OB, OGG1, OPG, OPN, OSM, OX40L, OX40R, p150, p95, PADPr, Parathyroid Hormone, PARC, PARP, PBR, PBSF, PCAD, P-Cadherin, PCNA, PD1, PDL1, PDGF, PDG F, PDK-1, PECAM, PEM, PF4, PGE, PGF, PGI2, PGJ2, PIN, PLA2, placental alkaline phosphatase (PLAP), P1GF, PLP, PP14, proinsulin, prorelaxin, protein C, PS, PSA, PSCA, prostate-specific membrane antigen (PSMA), PTEN, PTHrp, Ptk, PTN, R51, RANK, RANKL, RANTES, RANTES, relaxin A chain, relaxin B chain, renin, respiratory syncytial virus (RSV) F, RSVFgp, Ret, Rheumatoid Factor, RLIP76, RPA2, RSK, S100, SCF / KL, SDF-1, SERINE, Serum Albumin, sFRP-3, Shh, SIGIRR, SK-1, SLAM, SLPI, SMAC, SMDF, SMOH, SOD, SPARC, Stat, STEAP, STEAP-II, TACE, TACI, TAG-72 (Tumor-Associated Glycoprotein-72), TARC, TCA-3, T Cell Receptor (e.g., T Cell Receptor Alpha / Beta), TdT, TECK, TEM1, TEM5, TEM7, TEM8, TERT, Testicular PLAP-like Alkaline Phosphatase, TfR, TGF, TGF-Alpha, TGF-Beta, TGF-Beta Pan TGF-link R1(ALK-5), TGF-link R11, TGF-link RIIb, TGF-link RIII, TG F-link 1, TGF-link 2, TGF-link 3, TGF- Regulation of factor 4, TGF-factor 5, activator Ck-1 Recombinant Tie, TIMP, TIQ, TMEFF2, Tmpo, TMPRSS2, TNF, TNF-protein TNF-Link 2, TNFc, TNF-RI, TNF-RII, TNFRSF10A(TRAIL R1Apo-2、DR4)、TNFRSF10B(TRAIL R2DR5、KILLER、TRICK-2A、TRICK-B)、TNFRSF10C(TRAIL R3DcR1、LIT、TRID)、TNFRSF10D(TRAIL R4 DcR2、TRUNDD)、TNFRSF11A(RANK ODF R、TRANCE R)、TNFRSF11B(OPG OCIF、TR1)、TNFRSF12(TWEAK R FN14)、TNFRSF13B(TACI)、TNFRSF13C(BAFF R)、TNFRSF14(HVEM ATAR、HveA、LIGHT R、TR2)、TNFRSF16(NGFR p75NTR)、TNFRSF17(BCMA)、TNFRSF18(GITR AITR)、TNFRSF19(TROY TAJ、TRADE)、TNFRSF19L(RELT) TNFRSF1A(TNF). R1CD120a, p55–60, TNFRSF1B(TNF RII CD120b, p75–80), TNFRSF26(TNFRH3), TNFRSF3(LTbR TNF RIII, TNFC R), TNFRSF4(OX40 ACT35, TXGP1). R), TNFRSF5(CD40 p50), TNFRSF6(Fas Apo-1, APT1, CD95), TNFRSF6B(DcR3M68, TR6), TNFRSF7(CD27), TNFRSF8(CD30), TNFRSF9(4-1BB). CD137、ILA), TNFRSF21(DR6), TNFRSF22(DCTRAIL R2 TNFRH2), TNFRST23(DCTRAIL R1TNFRH1), TNFRSF25(DR3Apo-3, LARD, TR-3, TRAMP, WSL-1), TNFSF10(TRAIL).Apo-2 ligand (TL2), TNFSF11 (TRANCE / RANK ligand ODF, OPG ligand), TNFSF12 (TWEAK Apo-3 ligand, DR3 ligand), TNFSF13 (APRIL TALL2), TNFSF13B (BAFF BLYS, TALL1, THANK, TNFSF20), TNFSF14 (LIGHT HVEM ligand, LTg), TNFSF15 (TL1A / VEGI), TNFSF18 (GITR ligand AITR ligand, TL6), TNFSF1A (TNF-α Conectin, DIF, TNFSF2), TNFSF1B (TNF-β LTa, TNFSF1), TNFSF3 (LTb TNFC, p33), TNFSF4 (OX40 ligand gp34, TXGP1), TNFSF5 (CD40 ligand CD154, gp39, HIGM1, IMD3, TRAP), TNFSF6 (Fas ligand Apo-1 ligand, APT1 ligand), TNFSF7 (CD27 ligand CD70), TNFSF8 (CD30 ligand CD153), TNFSF9 (4-1BB ligand CD137 ligand), TP-1, t-PA, Tpo, TRAIL, TRAIL R, TRAIL-R1, TRAIL-R2, TRANCE, transfering receptor, TRF, Trk (e.g., TrkA), TROP-2, TSG, TSLP, tumor-associated antigen CA125, tumor-associated antigen expressing Lewis Y-associated carbohydrate, TWEAK, TXB2, Ung, UPAR, uPAR-1, urokinase, VCAM, VCAM-1, VECAD, VE-cadherin, VE-cadherin-2, VEFGR-1 (fit-1), VEGF, VEGFR, VEGFR-3 (flt-4), VEGI, VI M, viral antigens, VLA, VLA-1, VLA-4, VNR integrin, von Willebrand factor, WIF-1, WNT1, WNT2, WNT2B / 13, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, WNT16, XCL1, XCL2, XCR1, XCR1, XEDAR, XIAP, XPD, and receptors for hormones and growth factors.

[0178] In some embodiments, the binding domain specifically binds to one or more therapeutic targets or antigens in livestock animals, for example, but not limited to, ACE, ACE-2, activin, activin A, activin AB, activin B, activin C, activin RIA, activin RIA ALK-2, activin RIB ALK-4, Activin RIIA, Activin RIIB, ADAM, ADAM10, ADAM12, ADAM15, ADAM17 / TACE, ADAMS, ADAM9, ADAMTS, ADAMTS4, ADAMTS5, ANG, Ang, Angiotensin type 1 (AT1) receptor, Angiotensin type 2 (AT2) receptor, Atrial natriuretic factor, av / b3 integrin, b-ECGF, CD19, CD20, CD30, CD34, CD40, CD40L, CD47, COX, CTLA-4, EGFR (ErbB-1), EPO, Follicle-stimulating hormone, GDF-8 (Myostatin), GLP1, GLP2, GnRH, Growth hormone-releasing factor, IgE, IL, IL-1, IL-1 R, IL-2, IL-2R, IL-4, IL-4R, IL-5, IL-5R, IL-6, IL-6R, IL-8, IL-9, IL-10, IL-12, IL-13, IL -15, IL-17, IL-18, IL-18R, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, interleukin receptors (e.g., IL -1R, IL-2R, IL-4R, IL-5R, IL-6R, IL-8R, IL-9R, IL-10R, IL-12R, IL-13R, IL-15R, IL-17R, I L-18R, IL-21R, IL-22R, IL-23R, IL-25R, IL-31R, IL-33R), LAP(TGF-1), latent TGF-1, latent TGF-1Examples include bp1, LFA-1, nerve growth factor (NGF), NGFR, NGF-beta, OX40L, OX40R, PD1, PDL1, TGF, TGF-alpha, TGF-beta, TGF-beta Pan-specific, TGF-beta R1 (ALK-5), TGF-beta R11, TGF-beta RIIb, TGF-beta RIII, TGF-beta 1, TGF-beta 2, TGF-beta 3, TGF-beta 4, TGF-beta 5, TNF, TNF-alpha, TNF-alpha-beta, TNF-beta 2, TNFc, TNF-RI, TNF-RII, TNFRSF16 (NGFR p75NTR), TNFRSF9 (4-1BB CD137, ILA), VEFGR-1 (fit-1), VEGF, VEGFR, and VEGFR-3 (flt-4).

[0179] In some embodiments, one or more polypeptides may include proteins, where the protein is a therapeutic protein, such as EPO, CTLA4, LFA3, VEGFR1 / VEGFR3, IL-1R, IL-4R, a GLP-1 receptor agonist, or a thrombopoietin-binding peptide. In some embodiments, the therapeutic protein may be ACE, ACE-2, activin, activin A, activin AB, activin B, activin C, activin RIA, activin RIA ALK-2, or activin RIB ALK-4, Activin RIIA, Activin RIIB, ADAM, ADAM10, ADAM12, ADAM15, ADAM17 / TACE, ADAMS, ADAM9, ADAMTS, ADAMTS4, ADAMTS5, ANG, Ang, Angiotensin type 1 (AT1) receptor, Angiotensin type 2 (AT2) receptor, Atrial natriuretic factor, av / b3 integrin, b-ECGF, CD19, CD20, CD30, CD34, CD40, CD40L, CD47, COX, CTLA-4, EGFR (ErbB-1), EPO, Follicle-stimulating hormone, GDF-8 (Myostatin), GLP1, GLP2, GnRH, Growth hormone-releasing factor, IgE, IL, IL-1, IL-1 R, IL-2, IL-2R, IL-4, IL-4R, IL-5, IL-5R, IL-6, IL-6R, IL-8, IL-9, IL-10, IL-12, IL-13, IL -15, IL-17, IL-18, IL-18R, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, interleukin receptors (e.g., IL -1R, IL-2R, IL-4R, IL-5R, IL-6R, IL-8R, IL-9R, IL-10R, IL-12R, IL-13R, IL-15R, IL-17R, I L-18R, IL-21R, IL-22R, IL-23R, IL-25R, IL-31R, IL-33R), LAP(TGF-1), latent TGF-1, latent TGF-1These include bp1, LFA-1, nerve growth factor (NGF), NGFR, NGF-beta, OX40L, OX40R, PD1, PDL1, TGF, TGF-alpha, TGF-beta, TGF-beta Pan-specific, TGF-beta R1 (ALK-5), TGF-beta R11, TGF-beta RIIb, TGF-beta RIII, TGF-beta 1, TGF-beta 2, TGF-beta 3, TGF-beta 4, TGF-beta 5, TNF, TNF-alpha, TNF-alpha-beta, TNF-beta 2, TNFc, TNF-RI, TNF-RII, TNFRSF16 (NGFR p75NTR), TNFRSF9 (4-1BB CD137, ILA), VEFGR-1 (fit-1), VEGF, VEGFR, or VEGFR-3 (flt-4).

[0180] Pharmaceutical composition To prepare pharmaceutical or sterile compositions of one or more polypeptides described herein, one or more polypeptides may be mixed with pharmaceutically acceptable carriers or excipients. (See, for example, Remington's Pharmaceutical Sciences and US Pharmacopeia: National Formulary, Mack Publishing Company, Easton, Pa. (1984)).

[0181] Therapeutic and diagnostic formulations can be prepared, for example, in the form of lyophilized powders, slurries, aqueous solutions, or suspensions by mixing with acceptable carriers, excipients, or stabilizers (e.g., Hardman, et al. (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, NY; Gennaro (2000) Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, NY; Avis, et al. (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Tablets, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms Forms: Disperse Systems, Marcel Dekker, NY; Weiner and Kotkoskie (2000) Excipient Toxicity and Safety, Marcel Dekker, Inc., New York, NY (see reference). In some embodiments, one or more polypeptides of the present invention are diluted to an appropriate concentration with a sodium acetate solution at pH 5-6, and NaCl or sucrose is added for tonicity. Additional agents such as polysorbate 20 or polysorbate 80 may be added to enhance stability.

[0182] The toxicity and therapeutic efficacy of polypeptide compositions administered alone or in combination with other drugs are determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., LD 50 (A lethal dose for 50% of the population) and ED 50This can be determined by a procedure for determining the therapeutically effective dose (LD50%) in the population. The dose-to-toxicity ratio is the therapeutic index (LD50). 50 / ED 50 In certain embodiments, one or more polypeptides exhibiting a high therapeutic index are desirable. Data obtained from these cell culture assays and animal studies can be used to derive a range of dosages for use in livestock animals. Doses of such compounds are preferably ED with little or no toxicity. 50 This falls within the circulating concentration range. The dosage may vary within this range depending on the dosage form and route of administration used.

[0183] The mode of administration can vary. Preferred routes of administration include oral, rectal, transmucosal, intestinal, parenteral; intramuscular, subcutaneous, intradermal, intramedullary, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, intraocular, inhalation, inhalation, topical, cutaneous, transdermal, or intraarterial. In some embodiments, one or more polypeptides may be administered by an invasive route such as injection. In further embodiments, one or more polypeptides may be administered intravenously, subcutaneously, intramuscularly, intraarterially, intratumorally, or by inhalation, aerosol delivery.

[0184] The pharmaceutical compositions disclosed herein may be administered by infusion. Examples of well-known forms of implants and modules for administering pharmaceutical compositions include U.S. Patent No. 4,487,603 disclosing an implantable microinfusion pump for dispensing a drug at a controlled rate; U.S. Patent No. 4,447,233 disclosing a drug infusion pump for delivering a drug at a precise infusion rate; U.S. Patent No. 4,447,224 disclosing an implantable variable flow rate infusion device for continuous drug delivery; and U.S. Patent No. 4,439,196 disclosing a permeable drug delivery system having a multi-chamber compartment. Many other such implants, delivery systems, and modules are well known to those skilled in the art.

[0185] Alternatively or additionally, one or more polypeptides may also be administered topically, for example, by direct injection of antibodies, often in depot or sustained-release formulations, into joints or pathogen-induced lesions of arthritis characterized by immunopathology. Furthermore, one or more polypeptides may be administered via a targeted drug delivery system, for example, by liposomes coated with tissue-specific antibodies, targeting joints or pathogen-induced lesions of arthritis characterized by immunopathology. The liposomes are targeted to the affected tissue and selectively taken up by the affected tissue.

[0186] The administration regimen depends on several factors, including, but is not limited to, the age, weight, and physical condition of the livestock animal receiving or undergoing treatment, the serum or tissue turnover rate of the therapeutic antibody, the level of symptoms, the immunogenicity of one or more therapeutic polypeptides, and the accessibility of target cells in the biological matrix. In some implementations, the administration regimen delivers one or more therapeutic polypeptides sufficient to bring about improvement in the targeted disease state while simultaneously minimizing undesirable side effects. Therefore, the amount of biological agent delivered depends in part on one or more specific therapeutic polypeptides and the severity of the condition being treated. Guidance on selecting the appropriate dose of therapeutic antibodies is available (see, for example, Wawrzynczak Antibody Therapy, Bios Scientific Pub. Ltd, Oxfordshire, UK (1996); Milgrom et al. New Engl. J. Med. 341:1966-1973 (1999); Slamon et al. New Engl. J. Med. 344:783-792 (2001); Beniaminovitz et al. New Engl. J. Med. 342:613-619 (2000); Ghosh et al. New Engl. J. Med. 348:24-32 (2003); Lipsky et al. New Engl. J. Med. 343:1594-1602 (2000)).

[0187] Determining the appropriate dose of one or more polypeptides is done by those skilled in the art, for example, using parameters or factors known or estimated to influence the treatment in the art. Generally, administration is started at a dose somewhat lower than the optimal dose and then increased in small increments until the desired or optimal effect is achieved against any negative side effects. Important diagnostic indicators include, for example, symptoms of inflammation or the level of inflammatory cytokines produced.

[0188] Nucleic acids, vectors, host cells, and methods for producing them. This disclosure also includes one or more nucleic acids encoding one or more polypeptides described herein, one or more vectors comprising one or more nucleic acids, and host cells comprising one or more nucleic acids or one or more vectors.

[0189] One or more polypeptides described herein may be produced in bacterial or eukaryotic cells. Some polypeptides, e.g., Fab', can be produced in bacterial cells, e.g., E. coli cells. Polypeptides can also be produced in eukaryotic cells such as transformed cell lines (e.g., CHO, 293E, COS, 293T, Hela). In addition, polypeptides (e.g., scFv) can be expressed in yeast cells such as Pichia (e.g., Powers et al., J Immunol Methods. 251:123-35 (2001)), Hanseula, or Saccharomyces. To produce the antibody of interest, one or more polynucleotides encoding one or more polypeptides are constructed, introduced into one or more expression vectors, and then expressed in suitable host cells. To improve expression, the nucleotide sequence of the gene can be recoded without altering (or making minimal changes to, e.g., removal of C-terminal residues of the heavy or light chain) the amino acid sequence. Regions that may be subject to recoding include those related to translation initiation, codon usage frequency, and unintended mRNA splicing candidates. The polynucleotides encoding the Fc region variants described herein will be readily apparent to those skilled in the art.

[0190] Using standard molecular biology techniques, recombinant expression vectors (or multiple vectors) can be prepared, host cells can be transfected, transformants can be selected, host cells can be cultured, and polypeptides (e.g., antibodies) can be recovered.

[0191] When one or more polypeptides are expressed in bacterial cells (e.g., E. coli), the expression vector must have features that allow for the amplification of the vector in the bacterial cells. Furthermore, when E. coli such as JM109, DH5α, HB101, or XL1-Blue is used as the host, the vector must have a promoter capable of enabling sufficient expression in E. coli, such as the lacZ promoter (Ward et al., 341:544-546 (1989)), the araB promoter (Better et al., Science, 240:1041-1043 (1988)), or the T7 promoter. Examples of such vectors include, for example, the M13 vector, the pUC series vectors, pBR322, pBluescript, pCR-Script, pGEX-5X-1 (Pharmacia), "QIAexpress system" (QIAGEN), pEGFP, and pET (when this expression vector is used, the host is preferably BL21 expressing T7 RNA polymerase). The expression vector may contain a signal sequence for antibody secretion. In the case of production into the periplasm of E. coli, the pelB signal sequence (Lei et al.) al., J. Bacteriol., 169:4379 (1987)) can be used as a signal sequence for antibody secretion. In the case of bacterial expression, the expression vector can be introduced into bacterial cells using the calcium chloride method or electroporation method.

[0192] When one or more polypeptides are expressed in animal cells such as CHO, COS, and NIH3T3 cells, the expression vector includes promoters necessary for expression in these cells, such as the SV40 promoter (Mulligan et al., Nature, 277:108 (1979)) (e.g., early Simian virus 40 promoter), the MMLV-LTR promoter, the EF1α promoter (Mizushima et al., Nucleic Acids Res., 18:5322 (1990)), or the CMV promoter (e.g., human cytomegalovirus pre-early promoter). In addition to the nucleic acid sequence encoding the Fc region variant, the recombinant expression vector may contain additional sequences such as sequences that regulate vector replication in the host cell (e.g., origin of replication) and selection marker genes. Selection marker genes facilitate the selection of host cells into which the vector has been introduced (e.g., U.S. Patents 4,399,216, 4,634,665, and 5,179,017). For example, typically, selection marker genes confer resistance to drugs such as G418, hygromycin, or methotrexate to host cells into which the vector has been introduced. Examples of vectors containing selection markers include pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13.

[0193] In some embodiments, one or more polypeptides are produced in mammalian cells. Exemplary mammalian host cells for expressing one or more polypeptides include Chinese hamster ovary (CHO cells) (including dhfr-CHO cells described in Urlaub and Chasin (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220, and used with a DHFR selection marker, for example, as described in Kaufman and Sharp (1982) Mol. Biol. 159:601621), human fetal kidney 293 cells (e.g., 293, 293E, 293T), COS cells, NIH3T3 cells, lymphocyte cell lines, for example, NS0 myeloma cells and SP2 cells, and cells derived from transgenic animals, for example, transgenic mammals. For example, cells are mammary epithelial cells.

[0194] In an exemplary system for antibody expression, a recombinant expression vector encoding both the antibody heavy and light chains is introduced into dhfr-CHO cells via calcium phosphate transfection. Within the recombinant expression vector, the antibody heavy and light chain genes are operably ligated to enhancer / promoter regulatory elements (e.g., those derived from SV40, CMV, adenovirus, etc., e.g., a CMV enhancer / AdMLP promoter regulatory element or an SV40 enhancer / AdMLP promoter regulatory element) to drive high levels of gene transcription. The recombinant expression vector also contains the DHFR gene, which allows for the selection of vector-transfected CHO cells using methotrexate selection / amplification. The selected transformed host cells are cultured to express the antibody heavy and light chains, and the antibody is recovered from the culture medium.

[0195] Treatment method One or more polypeptides disclosed herein can be used to treat or prevent any disease or disorder in livestock animals in need. The present invention is particularly useful for treating chronic conditions requiring repeated administration. The increased half-life of the protein therapeutic agent may allow for a reduction in the frequency of administration and / or the dose level.

[0196] In some embodiments, the diseases, disorders, conditions, or symptoms treated or prevented are allergic diseases, chronic pain, acute pain, inflammatory diseases, autoimmune diseases, endocrine disorders, gastrointestinal disorders, skeletal / musculoskeletal disorders, cardiovascular diseases, neurological disorders, kidney diseases, metabolic disorders, immune disorders, genetic / hereditary disorders, reproductive function disorders, infections, or cancer. In certain embodiments, the diseases or disorders treated or prevented are atopic dermatitis, allergic dermatitis, food allergies, osteoarthralgia, perioperative pain, toothache, cancer pain, arthritis, anemia, obesity, or diabetes.

[0197] Antibodies can be used not only to treat or prevent diseases, but also to regulate normal biological functions, for example, to manage reproductive capacity or behavior.

[0198] diagnosis One or more polypeptides disclosed herein can also be used for a variety of diagnostic applications, for example, to determine whether a livestock animal has any particular disease or disorder. In some embodiments, one or more polypeptides may include a binding domain. The binding domain can specifically bind to proteins, subunits, domains, motifs, and / or epitopes (e.g., markers for cancer cells) described herein. In some embodiments, one or more polypeptides further include labeling groups. Generally, labeling groups can be divided into various types depending on the assay in which they are detected: a) isotopic labels which may be radioisotopes or heavy element isotopes; b) magnetic labels (e.g., magnetic particles); c) oxygen-reducing active moieties; d) optical dyes; enzymatic groups (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase); e) biotinylating groups; and f) predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal-binding domains, epitope tags, etc.). In some embodiments, the labeling group is bound to the antibody via spacer arms of varying lengths to reduce potential steric hindrance. Various methods for labeling proteins are known in the art and may be used in carrying out the present invention.

[0199] In some embodiments, the labeling group is a probe, a dye (e.g., a fluorescent dye), or a radioisotope (e.g., 3 H, 14 C, 22 Na, 36 Cl, 35 S, 33 P, or 125 I) is correct.

[0200] Certain labels also include, but are not limited to, optical dyes, including chromophores, phosphors, and fluorophores, the latter of which are often specific. Fluorophores can be either "small molecule" phosphors or protein-based phosphors.

[0201] A fluorescent label can be any molecule that can be detected through its intrinsic fluorescent properties. Suitable fluorescent labels include fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosine, coumarin, methyl-coumarin, pyrene, malacite green, stilbene, Lucifer Yellow, Cascade Blue J, Texas Red, IAEDANS, EDANS, BODIPY FL, LC Red 640, Cy 5, Cy 5.5, LC Red 705, Oregon green, Alexa-Fluor dyes (Alexa Fluor 350, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660, Alexa Fluor 680), Cascade Blue, Cascade Yellow, and R-phycoerythrin (PE) (Molecular Probes, Eugene, Oreg.), FITC, rhodamine, and Texas This includes, but is not limited to, Red (Pierce, Rockford, Ill.), Cy5, Cy5.5, and Cy7 (Amersham Life Science, Pittsburgh, Pa.). Suitable optical dyes, including fluorophores, are described in the Molecular Probes Handbook by Richard P. Haugland, which is incorporated herein by reference in its entirety.

[0202] Suitable protein-based fluorescent labels also include green fluorescent protein (including GFP from Renilla, Ptilosarcus, or Aequorea species) (Chalfie et al., 1994, Science 263:802-805), EGFP (Clontech Laboratories, Inc., GenBank accession number U55762), blue fluorescent protein (BFP, Quantum Biotechnologies, Inc., 1801 de Maisonneuve Blvd. West, 8th Floor, Montreal, Quebec, Canada H3H1J9; Stauber, 1998, Biotechniques 24:462-471; Heim et al., 1996, Curr. Biol. 6:178-182), improved yellow fluorescent protein (EYFP, Clontech Laboratories, Inc.), and luciferase (Ichiki et al. al., 1993, J.Immunol. 150:5408-5417), β-galactosidase (Nolan et al.) This includes, but is not limited to, U.S. Patent Nos. al., 1988, Proc. Natl. Acad. Sci. USA 85:2603-2607, and Renilla (WO92 / 15673, WO95 / 07463, WO98 / 14605, WO98 / 26277, WO99 / 49019, U.S. Patent Nos. 5,292,658, 5,418,155, 5,683,888, 5,741,668, 5,777,079, 5,804,387, 5,874,304, 5,876,995, and 5,925,558). All references cited above in this paragraph are expressly incorporated herein by reference in their entirety.

[0203] Assay FcγRI and FcγRIII binding: Binding to FcγRI and FcγRIII is an indicator of the ability of an antibody to mediate ADCC. To evaluate this property of an antibody, assays measuring the binding of the antibody to FcγRI and FcγRIII can be performed using methods known in the art. C1q binding:

[0204] Binding to C1q, the first component of complement, is an indicator of an antibody's ability to mediate complement-dependent cell-mediated cytotoxicity (CDC). To evaluate this property of an antibody, assays measuring the binding of an antibody to C1q can be performed using methods known in the art.

[0205] Half-life: Methods for measuring the half-life of antibodies are well known in the art. For example, see Booth et al., MAbs, 10(7):1098-1110 (2018). As an example, the half-life of an antibody can be measured by injecting the antibody into the species from which Fc originates (target species) and measuring the antibody level in the serum over a certain period of time. Alternatively, a transgenic mouse model can be used in which the mouse FcRn alpha chain is deficient and the target species' FcRn alpha transgene expresses the target species' FcRn alpha transgene. The target species' FcRn alpha chain can pair with the mouse β2-microglobulin protein, or the mouse β2-microglobulin gene can be replaced with the target species' β2-microglobulin gene, thereby forming a native FcRn alpha chain-β2-microglobulin heterodimer protein. [Examples]

[0206] Example 1: Generation of an NNK saturated mutation library at a selected location and analysis of individual variants. Wild-type (wt) sequences of the CH2 and CH3 domains of pig, cattle, horse, sheep, and goat IgG (shown in SEQ ID NOs: 1-27) were synthesized and used as templates for NNK mutagenesis. NNK saturated mutagenesis is an effective strategy for generating all 20 possible amino acids at the desired position (Hogrefe et al., Biotechniques. 33:1158-1165

[2002] ; its contents are incorporated herein by reference in their entirety). Individual NNK libraries were generated at positions 250, 252, 254, 256, 286, 309, 311, 426, 428, 434, and 436 (EU numbering). NNK (N=A / C / G / T, K=G / T) primers at specific positions were used with the QuikChange Site-Directed Mutagenesis Kit (Agilent). The PCR product is subcloned into a GenScript FASEBA plasmid, transformed into E. coli, and sequenced for the presence of the variant. Downstream of the CH2 domain is a SASA (single-domain antibody against serum albumin) tag with pM affinity to albumin (Zhang, J.; Wu, S.; Liu, J. Methods and systems for increasing protein stability. Patent application number: US2013 / 0129727A1; its contents are incorporated herein by reference in their entirety). The SASA antibody enables the capture of Fc to the sensor chip surface as described below. A PelB (pectin lyase B) signal peptide is located at the N-terminus and promotes the secretion of Fc into the culture medium. CH2-CH3 protein expression is regulated by the Lac promoter. The supernatant from the acclimatization medium is analyzed using surface plasmon resonance (SPR) for variant binding to the FcRn of the target livestock animal / species at pH 6.0.

[0207] The supernatants of multiple individual transformants obtained from each library are assayed for binding to livestock animal / species FcRn at pH 6.0 using the Biacore method as described below.

[0208] In SPR analysis using Biacore 8K, bovine serum albumin (BSA) is immobilized on a CM5 sensor tip. The sensor tip surfaces of flow cells 1 and 2 are activated over 420 seconds (10 μL / min) with a freshly mixed 50 mmol / L N-hydroxysuccinimide and 200 mmol / L 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride. Then, BSA diluted with 10 mM sodium acetate (pH 4.5) is injected into flow cell 2 to achieve conjugation, and flow cell 1 is used as a blank. After the amine coupling reaction, the active coupling site remaining on the tip surface is blocked by injecting 1 mM ethanolamine hydrochloride for 420 seconds. The running buffer for the coupling experiment is HBS-EP (10 mM HEPES, 500 mM NaCl, 3 mM EDTA, 0.05% Tween 20, pH 5.5), and the experiment is performed at 25°C. The variant supernatant is injected onto the tip surface and captured by the immobilized BSA via a SASA tag over 60 seconds. The FcRn of the livestock animal / species is injected at 200 nM for 120 seconds, and dissociation is performed with running buffer for 120 seconds. The flow rate for the BSA immobilization phase is 10 μl / min, and the flow rate for the association and dissociation phases is 30 μl / min. All data are processed using Biacore 8K evaluation software version 1.1. The results will indicate that the Fc variant of the tested IgG has increased binding affinity to the corresponding livestock animal / species FcRn at pH 6.0 compared to the Fc of wild-type IgG of the same livestock animal / species.

[0209] Example 2: Scanning mutation introduction of IgG Fc Using a phage display library approach, we identify IgG1 Fc variants that have increased affinity for the same livestock animal or species' FcRn at pH 6.0. IgG Fc (including the CH2+CH3 domains of SEQ ID NOs. 1-27) are synthesized by Twist Bioscience to generate multiple variants with one or more amino acid mutations (substitutions). Eight possible amino acid substitutions are made at each mutation site. These amino acids are arginine and lysine (positively charged side chains), aspartic acid and glutamic acid (negatively charged side chains), threonine and glutamine (polar uncharged side chains), and leucine and valine (hydrophobic side chains). Fc DNA libraries are designed to have an average of two variants per Fc molecule. The number of modification combinations can be calculated using the formula: nCr = n! / r!*(nr)! (where n represents the number of sites and r represents the number of variants per molecule). Fc variants containing the desired site-specific mutations are printed as mutagenic oligonucleotides on Twist's silicon-based platform.

[0210] Next, assembly PCR is used to ligate oligonucleotides and generate a full-length Fc gene fragment pool. Then, the ligated Fc gene fragment pool is cloned into the Sfi cleavage site of Antibody Design Labs' pADL-22c phagemide vector. The cloned DNA library is transformed into TG1 E. coli electrocompetent cells, typically >10 10 Experimental diversity of variants is created. Next, phagemid-transformed E. coli cells are co-transfected with the M13K07 helper phage to create a phage pool for use in protein-based panning. The library is resuspended in 20 mM MES buffer (pH 6.0), 0.05% Tween 20, and 3% milk.

[0211] The quality of the library is determined by selecting 96 random phage clones, which are then sequenced using the Sanger method.

[0212] In the initial phage selection, a protein A capture step is used to remove any Fc variants that have lost protein A binding. For this selection, the phage library is captured on protein A beads and washed with PBS (pH 7.4). The phages are eluted with 0.1 M glycine (pH 2.7) and the pH is immediately neutralized with 1 M Tris-HCl (pH 7.5). The neutralized phages are precipitated with polyethylene glycol / NaCl and centrifuged. The pelletized phages are resuspended in 20 mM MES (pH 6.0), 0.05% Tween 20, and 3% milk.

[0213] The following phage selection is based on the protocol described in Borrok et al., 2015, J Biol. Chem., 290:4282 (the entire content of which is incorporated herein by reference). Briefly, a Nunc 96 multiwell plate is coated with Nutroavidin and then blocked with 5% bovine serum albumin PBS (pH 7.4). Biotinylated FcRn of the target livestock animal or species is immobilized in the wells in PBS (pH 6.0) at a concentration of approximately 0.30 μg / ml. The phage library in PBS (pH 6.0) is incubated with the immobilized FcRn and then washed with PBS (pH 6.0), 0.05% Tween 20, and 0.3 M NaCl. The phages are eluted by incubation with PBS (pH 7.4) at 37°C for 30 minutes. The eluted phages are depleted at pH 7.4 with approximately 0.30 μg / ml of FcRn from the same livestock animal or species. Unbound phages are then grown in TG1 cells.

[0214] Next, the clones are sequenced using next-generation sequencing with Illumina MiSeq.

[0215] The unique variant can be reformatted to IgG, and the miniprep plasmid DNA can be transfected into Expi293 cells using the ExpiFectamine293 transfection reagent. The Ig variant can then be purified from the conditioned medium by protein A chromatography and adjusted to 43 mM sodium citrate, 130 mM sodium bicarbonate, and pH 6.0.

[0216] To determine the affinity of an IgG variant to the FcRn of a corresponding livestock animal / species, binding kinetics can be determined using a Carterra instrument. In this approach, the antibody (approximately 5 μg / ml) is amine-coupled to an HC30M sensor chip, typically by EDC / NHS activation followed by quenching with ethanolamine HCl.

[0217] FcRn at different concentrations (333 nM, 111 nM, 37 nM, 12.3 nM, 4.1 nM, 1.37 nM, 0.45 nM) was flowed onto a sensor tip in HBSTE (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% Tween-20), 0.5% bovine serum albumin, pH 6.0 to determine the kinetics at pH 6.0. The same strategy can be used to determine the binding kinetics to FcRn at pH 7.4, except that the pH of the HBSTE buffer is adjusted to 7.4.

[0218] Table 6 below provides a list of amino acid substitutions that increase the binding of IgG Fc variants to the corresponding FcRN of the same livestock animal / species: [Table 6]

[0219] Example 3: Binding kinetics of IgG Fc variants to FcRn Sets of Fc variants were expressed and purified from pig, sheep, bovine, and horse IgG. The variable domains of the heavy and light chains of each IgG were previously described by Gearing et al. (2016, J Vet Intern Med, 30:1129). The heavy and light chain constant domains used for IgG from various species were as follows: for pigs, IgG1a (Genbank AAA52219.1, SEQ ID NO: 1) and porcine kappa chain (Genbank AHB17990.1); for sheep, IgG1 (Genbank X69797, SEQ ID NO: 22) and sheep kappa chain (Genbank AU45094.1); for cattle, IgG1 (Genbank ABE68619.1, SEQ ID NO: 12) and bovine kappa chain (Genbank AEM45004.1); and for horses, IgG1 (Genbank CAC44760.1, SEQ ID NO: 15) and horse kappa chain (Genbank CAA53284.1). Variants were generated at positions 252, 286, 309, 311, 426, 428, 434, and 436 in various Fc cells (Figure 1) (EU numbering). Synthesized DNA for each variant and wild type was subcloned into pcDNA3.4 expression vectors (Life Technologies) and expressed in HEK293 cells. The conditioned media for each variant and wild type were purified with the resins shown in Table 7, and the purified antibodies were prepared in PBS (pH 7.2). All resins were obtained from Cytiva, except for RoboColumn Eshmuno A, which was purchased from EMD Millipore.

[0220] The purity of the antibodies was determined by scanning densitometry of SDS / PAGE gels stained with Coomassie blue, and each was >90% (Figures 2A-2J, 3A-3J, 4A-4J, 5A-5J). [Table 7]

[0221] The FcRn complex consists of the large subunit p51 and β-2-microglobulin. The Avi tag sequence (SEQ ID NO: 28, GLNDIFEAQKIEWHE) and the 8X His tag were fused to the C-terminus of the extracellular domain of the large subunit p51 (Pig: Genbank E9LK24; Sheep: Genbank Q8HZV2; Cattle: Genbank AAF60956.1; Horse: Genbank XP_023505908.1) and subcloned into the pcDNA3.4 expression vector (Life Technologies). The Flag tag (SEQ ID NO: 29, DYKDDDDK) was fused to the C-terminus of β-2-microglobulin (Pig: Genbank L13854.1; Sheep: Genbank AY549962.1; Cattle: Genbank X69084.1; Horse: Genbank X69083.1) and subcloned into the pcDNA3.4 expression vector. For each species, a large subunit p51 expression vector was cotransfected into HEK293 cells along with β-2-microglobulin. The FcRn complex was purified from conditioned medium using HisTrap first-flow chromatography (Cytiva), and the protein was then adjusted to PBS, pH 7.2. The protein was analyzed by SDS / PAGE and analytical SEC (size exclusion chromatography) using a TSKgel G3000SWxl column. Protein purity was >95% according to SDS / PAGE, and >95% of the FcRn complex was a heterodimer of large subunit p51 and β-2-microglobulin according to analytical SEC.

[0222] FcRn binding experiments were performed on a Biacore 8K+ system at 25°C. Polyclonal antibodies against the His tag were coupled to a CM5 biosensor chip using the His Capture Kit (Cytiva, Cat28995056) according to the manufacturer's instructions. His-tagged FcRn from various species was flowed at 10 μl / min on the anti-His polyclonal biosensor chip until approximately 100 RU were captured. Various swine, sheep, bovine, and horse FcRn protein IgG variants and wild-type proteins were used as analytes on the porcine, bovine, horse, and sheep FcRn protein biosensor chips. Five concentrations of IgG were injected at 30 μl / min for 90 seconds, with a dissociation time of 30 seconds. For each wild-type IgG, the IgG concentrations were 6.2 nM, 18 nM, 55 nM, 167 nM, and 500 nM. For each variant of IgG, the IgG concentrations were 1.2 nM, 3.7 nM, 11 nM, 33 nM, and 100 nM. The running buffer was 1X PBS-P+ (Cytiva, Cat#28995084) adjusted to pH 5.9. The surface was regenerated with 10 mM glycine (pH 1.5) at 30 μl / min for 30 seconds. Data were evaluated using Insight Evaluation Software by fitting to a 1:1 kinetic interaction model or to steady-state affinity.

[0223] Table 8 shows kinetic binding data for porcine IgG variants and wild-type IgG, and Figures 6A-6J show sensorgrams of the binding data. [Table 8]

[0224] Table 9 shows kinetic binding data for sheep IgG variants and wild-type, and Figures 7A to 7J show sensorgrams of the binding data. [Table 9]

[0225] Table 10 shows kinetic binding data for bovine IgG variants and wild-type IgG, and Figures 8A to 8J show sensorgrams of the binding data. [Table 10]

[0226] Table 11 shows kinetic binding data for equine IgG variants and wild-type, and Figures 9A to 9J show sensorgrams of the binding data. [Table 11]

[0227] Table 12 shows interspecies comparisons of the multiple increase of each Fc variant compared to the wild-type Fc. [Table 12]

[0228] Other Embodiments The present invention has been described in detail, but the above description is illustrative of the scope of the invention and is not intended to limit it. The present invention is defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

1. A polypeptide comprising a livestock IgG Fc region variant or an FcRn binding region thereof, said polypeptide comprising an amino acid substitution at at least one position selected from the group consisting of: (i) a position corresponding to amino acid position 309 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Q309V, Q309D and Q309E; (ii) a position corresponding to amino acid position 250 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of S250Q, S250E, T250Q, T250E, I250Q, I250E, A250Q, A250E, V250Q and V250E; (iii) a position corresponding to amino acid position 252 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of M252Y, M252W, M252F, T252Y, T252W, T252F, K252Y, K252W and K252F; (iv) a position corresponding to amino acid position 254 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of S254T, S254R, S254K, S254H, T254R, T254K and T254H; (v) a position corresponding to amino acid position 256 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of T256A, T256D, T256E, M256A, M256D, M256E, K256A, K256D and K256E; (vi) a position corresponding to amino acid position 286 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of S286Y, S286F, S286W, S286L, S286D, S286E, T286Y, T286F, T286W, T286L, T286D and T286E; (vii) a position corresponding to amino acid position 311 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, Q311H, E311V, E311K, E311R, E311L, E311H, K311V, K311R, K311L, K311H, D311V, D311K, D311R, D311L and D311H; (viii) a position corresponding to amino acid position 426 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of A426Y, A426F, A426H, V426Y, V426F, V426H, G426Y, G426F and G426H; (ix) a position corresponding to amino acid position 428 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of M428L, M428Y, M428F, H428L, H428Y and H428F; (x) a position corresponding to amino acid position 434 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W, N434Y, H434A, H434F, H434S, H434W and H434Y; and (xi) a position corresponding to amino acid position 436 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Y436H, T436H, F436H and V436H. Including, wherein the amino acid positions are based on EU numbering, and the polypeptide has increased binding affinity to FcRn of the livestock animal when compared to the Fc domain of the wild-type IgG.

2. the livestock animal is a horse; The polypeptide comprises an amino acid substitution at at least one position selected from the group consisting of: (i) a position corresponding to amino acid position 309 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Q309V, Q309D and Q309E; (ii) a position corresponding to amino acid position 250 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of T250Q, T250E, A250Q, A250E, V250Q and V250E; (iii) a position corresponding to amino acid position 252 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of M252Y, M252W, M252F, K252Y, K252W and K252F; (iv) a position corresponding to amino acid position 254 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of S254T, S254R, S254K, S254H, T254R, T254K and T254H; (v) a position corresponding to amino acid position 256 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of T256A, T256D, T256E, M256A, M256D, M256E, K256A, K256D and K256E; (vi) a position corresponding to amino acid position 286 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of S286Y, S286F, S286W, S286L, S286D, S286E, T286Y, T286F, T286W, T286L, T286D and T286E; (vii) a position corresponding to amino acid position 311 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, Q311H, K311V, K311R, K311L and K311H; (viii) a position corresponding to amino acid position 426 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of A426Y, A426F, A426H, V426Y, V426F, V426H, G426Y, G426F and G426H; (ix) a position corresponding to amino acid position 428 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of M428L, M428Y and M428F; (x) a position corresponding to amino acid position 434 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W, N434Y, H434A, H434F, H434S, H434W and H434Y; and (xi) a position corresponding to amino acid position 436 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Y436H, F436H and V436H. The polypeptide of claim 1 ,

3. The livestock animal is a pig, The polypeptide comprises an amino acid substitution at at least one position selected from the group consisting of: (i) a position corresponding to amino acid position 250 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of T250Q, T250E, I250Q and I250E; (ii) a position corresponding to amino acid position 252 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of M252Y, M252W and M252F; (iii) a position corresponding to amino acid position 254 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of S254T, S254R, S254K and S254H; (iv) a position corresponding to amino acid position 256 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of T256A, T256D and T256E; (v) a position corresponding to amino acid position 286 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of T286Y, T286F, T286W, T286L, T286D and T286E; (vi) a position corresponding to amino acid position 309 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Q309V, Q309D and Q309E; (vii) a position corresponding to amino acid position 311 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, Q311H, E311V, E311K, E311R, E311L and E311H; (viii) a position corresponding to amino acid position 426 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of A426Y, A426F, A426H, V426Y, V426F and V426H; (ix) a position corresponding to amino acid position 428 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of M428L, M428Y, M428F, H428L, H428Y and H428F; (x) a position corresponding to amino acid position 434 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of N434H, N434F, N434S, N434W, N434Y, H434A, H434F, H434S, H434W and H434Y; and (xi) a position corresponding to amino acid position 436 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Y436H and T436H. The polypeptide of claim 1 ,

4. The livestock animal is a cow, The polypeptide comprises an amino acid substitution at at least one position selected from the group consisting of: (i) a position corresponding to amino acid position 250 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of T250Q and T250E; (ii) a position corresponding to amino acid position 252 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of M252Y, M252W, M252F, T252Y, T252W and T252F; (iii) a position corresponding to amino acid position 254 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of S254T, S254R, S254K, S254H, T254R, T254K and T254H; (iv) a position corresponding to amino acid position 256 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of T256A, T256D and T256E; (v) a position corresponding to amino acid position 286 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of T286Y, T286F, T286W, T286L, T286D and T286E; (vi) a position corresponding to amino acid position 309 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Q309V, Q309D and Q309E; (vii) a position corresponding to amino acid position 311 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L and Q311H; (viii) a position corresponding to amino acid position 426 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of A426Y, A426F, A426H, V426Y, V426F and V426H; (ix) a position corresponding to amino acid position 434 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W and N434Y; and (x) a position corresponding to amino acid position 436 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is Y436H; The polypeptide of claim 1 ,

5. The livestock animal is a sheep, The polypeptide comprises an amino acid substitution at at least one position selected from the group consisting of: (i) a position corresponding to amino acid position 250 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of S250Q, S250E, T250Q and T250E; (ii) a position corresponding to amino acid position 252 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of M252Y, M252W, M252F, T252Y, T252W and T252F; (iii) a position corresponding to amino acid position 254 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of S254R, S254K, S254H, T254R, T254K and T254H; (iv) a position corresponding to amino acid position 256 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of T256A, T256D and T256E; (v) a position corresponding to amino acid position 286 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of T286Y, T286F, T286W, T286L, T286D and T286E; (vi) a position corresponding to amino acid position 309 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Q309V, Q309D and Q309E; (vii) a position corresponding to amino acid position 311 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, Q311H, D311V, D311K, D311R, D311L and D311H; (viii) a position corresponding to amino acid position 426 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of V426Y, V426F and V426H; (ix) a position corresponding to amino acid position 428 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of M428L, M428Y and M428F; (x) a position corresponding to amino acid position 434 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W and N434Y; and (xi) a position corresponding to amino acid position 436 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is Y436H; The polypeptide of claim 1 ,

6. The livestock animal is a goat, The polypeptide comprises an amino acid substitution at at least one position selected from the group consisting of: (i) a position corresponding to amino acid position 250 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of S250Q, S250E, T250Q and T250E; (ii) a position corresponding to amino acid position 252 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of M252Y, M252W, M252F, T252Y, T252W and T252F; (iii) a position corresponding to amino acid position 254 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of S254R, S254K, S254H, T254R, T254K and T254H; (iv) a position corresponding to amino acid position 256 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of T256A, T256D, T256E, K256A, K256D and K256E; (v) a position corresponding to amino acid position 286 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of T286Y, T286F, T286W, T286L, T286D and T286E; (vi) a position corresponding to amino acid position 309 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Q309V, Q309D and Q309E; (vii) a position corresponding to amino acid position 311 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of Q311V, Q311K, Q311R, Q311L, Q311H, K311V, K311R, K311L, K311H, D311V, D311K, D311R, D311L and D311H; (viii) a position corresponding to amino acid position 426 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of A426Y, A426F, A426H, V426Y, V426F and V426H; (ix) a position corresponding to amino acid position 428 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of M428L, M428Y and M428F; (x) a position corresponding to amino acid position 434 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is selected from the group consisting of N434A, N434H, N434F, N434S, N434W and N434Y; and (xi) a position corresponding to amino acid position 436 of a wild-type IgG of said livestock animal, wherein said amino acid substitution is Y436H; The polypeptide of claim 1 , (i) the livestock animal is a horse, and the Fc of the wild-type IgG is an Fc of equine IgG comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 15-21; (ii) the livestock animal is a pig, and the wild-type IgG Fc is a porcine IgG Fc comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-11; (iii) the livestock animal is a bovine, and the wild-type IgG Fc is a bovine IgG Fc comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12-14; (iv) the livestock animal is a sheep and the Fc of the wild-type IgG is an Fc of sheep IgG comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-24; or (v) The polypeptide of any one of claims 1 to 6, wherein the livestock animal is a goat and the Fc of the wild-type IgG is a Fc of a goat IgG comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 25 to 27.

8. 8. The polypeptide of claim 1, wherein the polypeptide comprises two or more of the at least one amino acid substitutions, the two or more amino acid substitutions being in different positions, and the polypeptide has increased binding affinity to FcRn of the livestock animal when compared to (a) the Fc domain of the wild-type IgG of the livestock animal, and (b) a polypeptide comprising only one of the two or more amino acid substitutions.

9. further comprising a binding domain, 9. The polypeptide of any one of claims 1 to 8, wherein the binding domain comprises: (i) the six complementarity determining regions (CDRs) of an immunoglobulin molecule; (ii) a ligand binding domain of the livestock receptor protein; (iii) a nanobody; or (iv) an extracellular domain of the livestock receptor protein.

10. 10. The polypeptide of claim 9, wherein the binding domain specifically binds to an antigen selected from the group consisting of NGF, TrKA, ADAMTS, IL-1, IL-2, IL-4, IL-4R, angiotensin type 1 (AT1) receptor, angiotensin type 2 (AT2) receptor, IL-5, IL-12, IL-13, IL-31, IL-33, CD3, CD20, CD47, CD52, and complexes of the complement system.

11. 11. The polypeptide of any one of claims 1 to 10, further comprising a protein selected from the group consisting of EPO, CTLA4, LFA3, VEGFR1 / VEGFR3, IL-1R, IL-4R, GLP-1 receptor agonist, and thrombopoietin binding peptide.

12. The polypeptide of any one of claims 1 to 11, wherein the polypeptide binds to FcRn of the livestock animal at a higher level at acidic pH than at neutral pH. (a) the polypeptide binds to FcRn of the livestock animal at a higher level at pH 5.5 than at pH 7.4; or 13. The polypeptide of claim 12, wherein (b) the polypeptide binds to FcRn of the livestock animal at a higher level at pH 6.0 than at pH 7.

4.

14. A pharmaceutical composition comprising (i) a polypeptide according to any one of claims 1 to 13, and (ii) a pharma- ceutically acceptable excipient.

15. A nucleic acid encoding a polypeptide according to any one of claims 1 to 13.

16. An expression vector comprising the nucleic acid of claim 15.

17. 17. A host cell comprising the nucleic acid of claim 15 or the expression vector of claim 16.

18. 1. A method of making a polypeptide comprising the steps of: (a) providing a nucleic acid according to claim 15; (b) expressing the nucleic acid in a host cell culture, thereby producing the polypeptide; and (c) recovering the polypeptide produced in (b) from the host cell culture. The method comprising:

19. 20. The method of claim 18, further comprising formulating the polypeptide as a pharmaceutical preparation.

20. A method for treating or preventing a disease or disorder in a livestock animal in need thereof, comprising administering to the livestock animal an effective amount of a composition comprising the pharmaceutical composition of claim 14.

21. The disease or disorder is (a) an allergy, chronic pain, acute pain, an inflammatory disease, an autoimmune disease, an endocrine disorder, a gastrointestinal disorder, a cardiovascular disease, a renal disease, a reproductive disorder, an infectious disease, or cancer; or 21. The method of claim 20, wherein (b) the condition is atopic dermatitis, allergic dermatitis, osteoarthritic pain, arthritis, anemia, or obesity.